Integrity of the short arm of nuclear pore Y-complex is required for mouse embryonic stem cell growth and differentiation

Running title: Roles of Y-complex Nups in mESCs

Alba Gonzalez-Estevez [1,2,3,#], Annalisa Verrico[1,#], Clarisse Orniacki [1,2], Bernardo Reina-San-Martin[3-6] and Valérie Doye[1,2*]

[1] Université de Paris, CNRS, Institut Jacques Monod, F-75006 Paris, France

[2] Ecole Doctorale BioSPC, Université de Paris, Paris, France

[3] present address : MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh EH4 2XU, UK

[4] Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Illkirch, 67404, France

[5] Inserm U 1258, Illkirch, 67404, France

[6] CNRS UMR 7104, Illkirch, 67404, France

[7] Université de Strasbourg (UDS), Illkirch, 67404, France

[#] These authors contributed equally

*Corresponding author and lead contact: valerie.doye@ijm.fr

Keywords:

Nucleoporin, Seh1, Nup43, Nup85, Mios, mouse embryonic stem cells.

Summary statement

Seh1 and Nup43, although dispensable in pluripotent mouse embryonic stem cells , are required for normal cell growth, viability upon differentiation, and maintenance of proper NPC density.

Abstract

Many cellular processes, ranging from cell division to differentiation, are controlled by nuclear pore complexes (NPCs). However studying contributions of individual NPC subunits to these processes in vertebrates has long been impeded by their complexity and the lack of efficient genetic tools. Here we use genome editing in mouse embryonic stem cells (mESCs) to characterize the role of NPC structural components, focusing on the short arm of the Y-complex that comprises Nup85, Seh1 and Nup43. We show that Seh1 and Nup43, although dispensable in pluripotent mESCs, are required for their normal cell growth rates, their viability upon differentiation, and for the maintenance of proper NPC density. mESCs with an N-terminally truncated Nup85 mutation (in which interaction with Seh1 is greatly impaired) feature a similar reduction of NPC density. However, their proliferation and differentiation are unaltered, indicating that it is the integrity of the Y-complex, rather than the number of NPCs, that is critical to ensure these processes.

List of Symbols and Abbreviations used.

mAID: mini Auxin Inducible Degron; mESC: mouse embryonic stem cell ; NE: nuclear envelope; NPC: Nuclear pore complex; Nups: nucleoporins ; n.s.: not significant; SD: standard deviation; *Tigre* locus: *Tightly regulated* locus ; WT: Wild type.

INTRODUCTION

Nuclear pore complexes (NPCs) are huge structures embedded in the nuclear envelope (NE). They provide the sole gateways for bidirectional nucleocytoplasmic transport, but also participate in a wide variety of other cellular processes including cell division and gene regulation (reviewed in Buchwalter et al., 2019; Hezwani and Fahrenkrog, 2017). NPCs are composed of ~ 30 distinct proteins (called nucleoporins or Nups), each present in multiple copies and forming a ring with an eightfold rotational symmetry. Among them, structural Nups assemble to form a scaffold that anchors Nups with unfolded domains, cytoplasmic filaments and the nuclear basket (reviewed in Hampoelz et al., 2019; Lin and Hoelz, 2019).

The three-dimensional organization of the NPC scaffold has been determined at atomic resolution (reviewed in (Hampoelz et al., 2019; Lin and Hoelz, 2019). It is formed by an inner rim sandwiched by two outer (cytoplasmic and nuclear) rims, whose main component is the evolutionarily-conserved Y-complex. In metazoans, this complex (also named Nup107-160 complex) comprises Nup133, Nup107, Nup96 and Sec13 (forming the stem of the Y); Nup160, Nup37 and Elys (building the long arm); and Nup85, Seh1 (also named Seh1l) and Nup43 (forming the short arm)(**Fig. 1A**) (Loiodice et al., 2004; Rasala et al., 2006; von Appen et al., 2015).

Functional studies in vertebrates have shown that the Y-complex is critical for NPC assembly, both after mitosis and during interphase (Doucet et al., 2010; Harel et al., 2003; Walther et al., 2003). Studies in mammalian cells also showed that in mitosis a fraction of the Y-complex localizes at kinetochores (Loiodice et al., 2004; Rasala et al., 2006) where it is required for proper chromosome congression and segregation (Platani et al., 2009; Zuccolo et al., 2007). Because the members of the Y-complex (Y-Nups) are tightly associated throughout the cell cycle (Loiodice et al., 2004; Rabut et al., 2004), they were long anticipated to work as an entity. However, one of its components, Sec13, is also part of the COPII coat complex involved in vesicle budding (Salama et al., 1993). In addition, Sec13 and Seh1 also belong to the unrelated GATOR2 complex, an indirect regulator of the mTORC1 pathway that controls cell growth and proliferation (Bar-Peled et al., 2013), further complicating the study of their function in the context of the Y-complex.

80 In mice, inactivation of most Y-Nups genes (namely *Elys*, *Nup96*, *Nup133*, *Nup85*,
81 *Sec13* and *Seh1*, but not *Nup37)* lead to embryonic lethality (Faria et al., 2006; Liu et
82 al., 2019; Lupu et al., 2008; Moreira et al., 2015; Okita et al., 2004; Terashima et al.,
83 2020; https://www.mousephenotype.org/data/genes/MGI:1919964). In particular,
84 Nup133 was found to be essential for mouse development beyond gastrulation
85 (Lupu et al., 2008). Studies performed in mouse embryonic stem cell (mESCs)
86 showed that Nup133 is dispensable for cell growth at the pluripotent stage, but is
87 required for mESC differentiation (Lupu et al., 2008). In mESCs, Nup133 is
88 dispensable for NPC scaffold assembly but required for the proper assembly of the
89 nuclear pore basket (Souquet et al., 2018). However, it is not clear if the role of
90 Nup133 in NPC basket assembly underlies its functions in cell differentiation.

91 More recently, Seh1, which is critical for proper mitotic progression in cancer cell
92 lines (Platani et al., 2018; Platani et al., 2009; Zuccolo et al., 2007), was found to be
93 required for differentiation of oligodendrocyte progenitors (Liu et al., 2019).
94 However, the potential contribution of Seh1 to cell cycle progression in non-
95 transformed cells and at other stages of cell differentiation needed to be addressed.

96 Here we assessed the requirements for Seh1 in pluripotent mESCs and upon their
97 differentiation towards neuroectodermal lineage, determined whether these
98 requirements reflect its role in the GATOR2-complex or in the short arm of the Y-
99 complex, and further addressed the specific function of these proteins in NPC
100 integrity. This systematic analysis enabled us to disentangle the processes underlying
101 the contribution of these of these Y-Nups in NPC assembly, nuclear size, cell growth
102 and differentiation.

103

103 ## Results

104 **Seh1 is required for mESC growth and survival upon differentiation**

105 Using CRISPR/Cas9 gene-editing technology we obtained several independent *Seh1*$^{-/-}$
106 mESC clones (of which three were further examined in this study; see Materials and
107 Methods and Table S2) (**Fig. 1B**). This indicates that Seh1 is dispensable for mESC
108 viability at the pluripotent stage. We noticed however that *Seh1*$^{-/-}$ mESCs formed
109 smaller colonies than did *WT* mESCs (**Fig. 1C**). Consistently, automated cell growth
110 analyses of *Seh1*$^{-/-}$ mESCs showed a clear reduction of cell confluence compared to
111 *WT* (**Fig. 1D**). More strikingly, *Seh1*$^{-/-}$ cells showed a strong impairment in viability
112 from the very early stages of monolayer differentiation towards neuroectodermal
113 lineage and almost no cells were recovered after 5 days (**Fig. 1E and Movies S1-S2**).

114 To verify the specificity of these phenotypes, we next integrated at the permissive
115 *Tigre* locus (Tightly regulated; Zeng et al., 2008) of *Seh1*$^{-/-}$ mESCs a GFP-tagged *Seh1*
116 cDNA expressed under the control of the pCAG promoter. The resulting cell lines
117 (subsequently named "*Rescue*" #1 and #2) expressed GFP-Seh1 at a level comparable
118 to that of the endogenous untagged protein (**Fig. 1B**). We observed a specific
119 enrichment of GFP-Seh1 at nuclear pores in interphase and at kinetochores
120 throughout mitosis (**Fig. 1F**). Most importantly, the growth rate of the *Rescue* cell
121 lines was comparable to that of *WT* cells both at the pluripotent stage (**Fig. 1D**) and
122 upon neuroectodermal differentiation (**Fig. 1E and Movie S3**).

123 To exclude the possibility that phenotypes observed in *Seh1*$^{-/-}$ mESCs at the
124 pluripotent stage could be due to cell adaptation, we also generated cell lines in
125 which endogenous *Seh1* was N-terminally tagged with the 7 kDa mini Auxin Inducible
126 Degron (mAID) sequence, to induce its acute degradation upon auxin addition
127 (Natsume et al., 2016). A GFP tag was also introduced to allow visualization of both
128 the localization and degradation of the resulting GFP-mAID-Seh1 fusion. Upon
129 addition of auxin to *GFP-mAID-Seh1* mESCs, the GFP signal rapidly declined in mitotic
130 cells whereas, as also previously observed in HCT116 cells (Platani et al., 2018), the
131 decay was more progressive in interphasic cells (**Fig. S1 A-D**). While the *GFP-mAID-*
132 *Seh1* clones showed normal cell growth and differentiation properties in control

133 conditions, addition of auxin recapitulated both the cell growth and differentiation
134 defects observed in *Seh1*$^{-/-}$ mESCs (**Fig. S1 E, F)**.
135
136 Together these data reveal that the lack of Seh1 specifically causes an impaired cell
137 growth of mESCs at the pluripotent stage and drastically reduced viability upon
138 induction of neuroectodermal differentiation.
139

140 **The altered growth rate of pluripotent *Seh1*$^{-/-}$ mESCs is mainly caused by extended**
141 **interphases.**

142 Seh1 is known to play a role in mitosis in cancer cell lines, in which its depletion
143 causes a delay in mitotic progression associated with chromosome congression and
144 segregation defects (Platani et al., 2018; Platani et al., 2009; Zuccolo et al., 2007).
145 Whether these defects are caused by the mislocalization of the entire Y-complex
146 from kinetochores, as observed in HeLa cells (Platani et al., 2009; Zuccolo et al.,
147 2007) or by the removal of Seh1 alone has recently been questioned (Platani et al.,
148 2018). To study the mitotic role of Seh1 in mESCs, *WT* and *Seh1*$^{-/-}$ cells were
149 transfected with GFP-H2B and imaged for 4-6 hours. Quantification of progression
150 time from prometaphase to anaphase onset showed a ~10 min delay in *Seh1*$^{-/-}$ as
151 compared to *WT* mESCs (from 23.7 ± 10.1 min in *WT* to 32.8 ± 14.5 min in Seh1$^{-/-}$
152 cells; mean±SD) (Fig. S2 A). This delay is clearly milder than the one initially reported
153 upon RNAi-induced depletion of Seh1 in HeLa cells (~45 to 60 min; Platani et al.,
154 2009; Zuccolo et al., 2007) but comparable to the delay recently measured upon
155 conditionally-induced degradation of Seh1 in a HCT116-derived cell line (~12 min;
156 Platani et al., 2018). In *Seh1*$^{-/-}$ or auxin-treated *GFP-mAID-Seh1* mitotic mESCs, the Y-
157 complex (visualized by Nup133 and Nup85) was still properly localized at
158 kinetochores despite the complete lack of Seh1 (**Figs. S1C** and **S2 B,C**). This indicates
159 that the mitotic delay observed in Seh1-deficient mESCs is not merely caused by the
160 mislocalization of the Y-complex from kinetochores.

161 The 10-minute prolongation of mitosis was however unlikely to explain the cell
162 growth defect of *Seh1*$^{-/-}$ mESCs (**Fig. 1C,D**). We therefore also measured the length of
163 interphase by imaging mCherry-H2B-expressing mESCs during 24-30 hours.

164 Quantification of progression time from the end of one mitosis (set at anaphase
165 onset) to the beginning of the next (set at prometaphase) showed that interphase
166 length is significantly longer in *Seh1*$^{-/-}$ as compared to *WT* mESCs (9.4 ± 2.2 hours in
167 *WT* versus 14.0 ± 4.5 and 14.1 ± 2.1 hours in *Seh1*$^{-/-}$ #1 and #2, respectively; means ±
168 SD) (**Fig. 2A**).
169 To determine if the lengthening of interphase in *Seh1*$^{-/-}$ mESCs was caused by
170 retention in a specific phase of the cell cycle, we analyzed EdU-labelled and DAPI-
171 stained *WT* and *Seh1*$^{-/-}$ mESCs by imaging flow cytometry (**Figs. 2B** and **S2D**). Except
172 for a mild increase in the percentage of the mitotic fraction, this analysis revealed a
173 comparable distribution of the G1, S and G2 phases of the cell cycle between *Seh1*$^{-/-}$
174 and *WT* mESCs (**Fig. 1H**). Therefore, the altered growth rate of *Seh1*$^{-/-}$ mESCs reflects
175 a lengthening distributed over all phases of the cell cycle.
176
177 **Lack of Seh1 leads to a decrease of both NPC density and nuclear size**
178 The viability of *Seh1*$^{-/-}$ mESCs at the pluripotent stage and their impaired survival
179 upon differentiation was reminiscent of the phenotype observed upon inactivation
180 of Nup133, another member of the Y-complex (Lupu et al., 2008). Because Nup133
181 loss was recently demonstrated to affect NPC basket assembly (as revealed by lack of
182 TPR staining in about 50% of the NPCs) (Souquet et al., 2018), we decided to
183 examine the impact of *Seh1* inactivation on NPC assembly. We therefore quantified
184 the average fluorescence intensity at the nuclear envelope (NE) of TPR, Nup98 and
185 Nup133 in *WT* and *Seh1*$^{-/-}$ mESCs, using a GFP-tagged cell line for internal reference,
186 as previously reported (Souquet et al., 2018; see Materials and Methods). This
187 analysis revealed a mild but significant reduction (in the range of 20-35%) of the
188 signal of these three nucleoporins in *Seh1*$^{-/-}$ relative to *WT* mESCs (**Fig. 3 A-C**). The
189 fact that the reduced intensity at the NE is not restricted to TPR indicates that, unlike
190 what was previously observed in *Nup133*$^{-/-}$ mESCs, the lack of Seh1 leads to a
191 decrease in the total number of NPCs rather than alteration of a specific
192 substructure. This defect in NPC density was also observed upon auxin-induced
193 depletion of Seh1 (**Fig. 3D**) and was largely rescued by stable expression of GFP-Seh1
194 (**Fig. 3, A-C**).

195 It was recently proposed that nuclear size is sensitive to NPC density and nuclear
196 import capacity in cultured mammalian cells (Jevtić et al., 2019). The decreased NPC
197 density observed upon Seh1 inactivation thus prompted us to measure nuclear size
198 in these mutant mESCs. This analysis revealed a ~10% reduction of the nuclear
199 surface in *Seh1*$^{-/-}$ mESCs, a phenotype that was rescued by the GFP-Seh1 transgene
200 (**Fig. 4A**). A significant reduction in nuclear size could also be observed in auxin-
201 treated *GFP-mAID-Seh1* mESCs (**Fig. 4B**).

202 *Seh1*-deficient mESCs thus exhibit several distinct phenotypes: altered cell growth,
203 lethality upon differentiation, reduced NPC density and nuclear size. We next aimed
204 to determine whether these defects were linked to each other and whether they
205 reflected functions of Seh1 as part of the Y-complex or the GATOR2 complex, or
206 both.

207

208 **Mios is not required for proper cell growth and cell differentiation in mESCs.**

209 Within the GATOR2 complex, Seh1 directly interacts with Mios (also known as Mio,
210 missing oocyte in Drosophila and Sea4 in budding yeast) (Senger et al., 2011; Bar-
211 Peled et al., 2013; Algret et al., 2014). Our western blot analyses revealed decreased
212 protein levels of Mios in *Seh1*$^{-/-}$ compared to *WT* mESCs (**Fig. 5A)**, a result consistent
213 with studies in other species and cell types (Platani et al., 2018; Platani et al., 2015;
214 Senger et al., 2011). To assess if this reduction in Mios could cause the cell growth
215 and differentiation phenotypes observed in *Seh1*$^{-/-}$ mESCs, we inactivated *Mios* in
216 mESCs via CRISPR/Cas9 (**Fig. 5A** and **Table S2**). Immunoprecipitation experiments
217 performed using anti-Seh1 antibodies revealed that lack of Mios prevents Seh1
218 interaction with Wdr24, another GATOR2 complex component (Bar-Peled et al.,
219 2013) (**Fig. 5B**). This points to Mios as being the main direct partner linking Seh1 to
220 the rest of the GATOR2 complex, a result complementing data previously obtained in
221 budding yeast and drosophila (Algret et al., 2014; Dokudovskaya and Rout, 2015; Cai
222 et al., 2016). Analyses of independent *Mios*$^{-/-}$ clones revealed only a minor reduction
223 of cell growth at the pluripotent stage as compared to *WT* mESCs (14±15% decrease
224 in confluence after 48h of growth, while the reduction was 44±14% for *Seh1*$^{-/-}$
225 mESCs; **Fig. 5C**). In addition, *Mios*$^{-/-}$ cells underwent differentiation towards the

226 neuroectodermal lineage with a comparable cell density (**Fig. 5D**) and morphology
227 (our unpublished data) as *WT* cells. Finally, quantitative analyses did not reveal any
228 significant alteration in either NPC density or nuclear size in *Mios*$^{-/-}$ as compared to
229 *WT* mESCs (**Fig. 5E, F**).
230 Together these experiments indicate that neither the growth and differentiation
231 defects, nor the altered nuclear pore density and nuclear sizes observed in *Seh1*$^{-/-}$
232 mESCs can be merely attributed to the decreased levels of Mios.

233

234 **Mutations affecting the short arm of the Y-complex impair NPC assembly, but with**
235 **distinct impacts on cell proliferation and differentiation**

236 Having excluded Mios destabilization as the main cause of the defects of *Seh1*$^{-/-}$
237 mESCs, we next focused our attention on Seh1's partners localized on the short arm
238 of the Y-complex (**Figs. 1A** and **6A**).

239 We first inactivated *Nup43*, another small β-propeller-folded nucleoporin that is
240 specific to metazoan Y-complexes (Neumann et al., 2010). We obtained viable clones
241 upon CRISPR/Cas9-mediated *Nup43* knockout in mESCs that however displayed
242 impaired proliferation at the pluripotent stage (**Fig. 6B, C**). Although this growth
243 defect was milder than the one observed in pluripotent *Seh1*$^{-/-}$ mESCs, *Nup43*$^{-/-}$
244 nevertheless underwent drastic cell death upon neuroectodermal differentiation,
245 comparable to that of differentiating *Seh1*$^{-/-}$ cells (**Fig. 6D**). *Nup43*$^{-/-}$ mESCs also
246 displayed a reduced NPC density comparable to that observed in the various *Seh1*$^{-/-}$
247 mESC lines, as revealed by the reduced intensity of Nup133, Nup98 and TPR labelling
248 at nuclear pores (**Fig. 7A-C**, see also **Fig. 2A-C**). Finally, these cells showed no
249 significant reduction in nuclear size (**Fig. 7D**). Together these data indicate that
250 inactivation of *Nup43* mimics, albeit with a slightly milder impact, most of the
251 phenotypes caused by *Seh1* inactivation.

252 To determine whether these shared phenotypes reflect a function of these Nups
253 within the short arm of the Y-complex, we next aimed to impair Seh1 recruitment to
254 the NPCs. Structural studies have shown that budding yeast Seh1 binds to Nup85
255 through its N-terminal domain forming the 7th blade to complete the β-propeller

256 structure of Seh1 (Brohawn et al., 2008; Debler et al., 2008). Homology modelling
257 predicted that the human Nup85-Seh1 interface similarly involves ß-sheets within
258 Nup85 N-terminal domain that complete Seh1 ß-propeller (von Appen et al., 2015);
259 see **Fig. 6A**). We thus attempted to prevent Seh1 binding to Nup85 by deleting most
260 of this blade (two β-sheets encoded by exon 2 of mouse Nup85; colored in yellow in
261 **Fig. 6A**) and inserting instead the sequence of the bulky GFP. We obtained viable
262 mESC lines in which the resulting ΔE2-GFP-Nup85 fusion, expressed as the unique
263 form of Nup85 in the cell (**Figs. 6B** and **S3C)**, was properly localized at both NPCs and
264 kinetochores (**Fig. S3A**).

265 To determine whether this deletion within Nup85 indeed prevented its interaction
266 with Seh1, we performed immunoprecipitation on *WT* or *ΔE2-GFP-Nup85* mESC
267 lysates using antibodies directed against either Nup85 itself, or Nup107, another Y-
268 complex constituent (**Fig. 1A**). Mass-spectrometry analysis showed that ΔE2-GFP-
269 Nup85 interacts with all the members of the Y-complex except Seh1 (**Fig. S3B**).
270 Because none of the available Seh1 antibodies we tested properly recognized
271 endogenous mouse Seh1 in immunofluorescence experiments, we also introduced
272 within *GFP-Seh1* cells the same N-terminal deletion of Nup85, this time tagged with
273 mCherry (**Fig. S3C** and **Table S2**). Although ΔE2-mCherry-Nup85 was properly
274 localized at NPCs and kinetochores (**Fig. 8A,B**), GFP-Seh1 was at most only barely
275 detectable at kinetochores in these cells (**Fig. 8B,D**; quantifications revealed 7-8 ± 5-
276 7% residual signal in ΔE2-mCherry-Nup85- compared to wt-Nup85-expressing cells).
277 The mislocalization of Seh1 from kinetochores is consistent with its impaired
278 interaction with ΔE2-GFP-Nup85 seen at the biochemical level and with previous
279 studies indicating that the Y-complex is recruited as an entity to kinetochores
280 (Loiodice et al., 2004). In contrast, we could still detect some punctate GFP-Seh1
281 signal at the nuclear envelope (26-27% residual signal; **Fig. 8A,C**). The relative
282 persistence of GFP-Seh1 at NPCs as compared to kinetochores in *ΔE2-mCherry-*
283 *Nup85* cells likely reflects the existence of additional minor binding sites for Seh1 at
284 NPCs, that either involve Nups not belonging to the Y-complex, or imply interfaces
285 generated by the 3D-organization of Y-complex within the assembled mammalian
286 NPC (Huang et al., 2020; Kosinski et al., 2016; von Appen et al., 2015).

287 Unexpectedly, analysis of cell differentiation did not reveal any significant
288 differences between *ΔE2-GFP-Nup85* and *WT* mESCs (**Fig. 6D**). In addition *ΔE2-GFP-*
289 *Nup85* mESCs only displayed a minor cell growth defect in the pluripotent state
290 (9±7% decrease in confluence after 48h of growth compared to *WT* mESCs, while the
291 reduction was 60±7% and 38±11% for *Seh1*$^{-/-}$ and *Nup43*$^{-/-}$ cells, respectively; **Fig. 6C**).
292 Nevertheless, pluripotent *ΔE2-GFP-Nup85* cells display a significant reduction in the
293 intensity of Nup133, Nup98 and TPR at the nuclear envelope (**Fig. 7A-C**). These
294 decreased signals were comparable to those observed in *Seh1*$^{-/-}$ and *Nup43*$^{-/-}$ mESCs,
295 and yet, as in the case of *Nup43*$^{-/-}$, they were not accompanied by a significant
296 reduction in nuclear size (**Fig. 7D**). Analysis of the *ΔE2-GFP-Nup85* cells lines thus
297 showed that perturbed recruitment of Seh1 at NPCs leads to a reduction in NPC
298 number, but does not impact cell growth and differentiation.

299

300 ## Discussion

301 This study has revealed that Seh1 and Nup43 are dispensable for mESC viability in
302 the pluripotent state but become critical upon their differentiation. In view of the
303 reported embryonic lethality of the *Seh1* knockout in mouse, an impaired
304 differentiation of *Seh1*$^{-/-}$ mESCs could have been anticipated (Liu et al., 2019). In
305 contrast, no role in development had been previously described for Nup43, which is
306 specific to metazoans (Neumann et al., 2010). Although the requirement for
307 differentiation was reminiscent of the phenotype observed upon inactivation of
308 *Nup133,* we observed that Seh1 and Nup43, are, unlike Nup133 (Lupu et al., 2008),
309 also required for proper growth of mESCs in the pluripotent state. Importantly, this
310 altered growth is not simply caused by a mitotic defect, as might have been assumed
311 given the mitotic roles of Seh1 in cancer cells (Platani et al., 2018; Platani et al.,
312 2009; Zuccolo et al., 2007), but rather reflects a lengthening of all phases of the cell
313 cycle.

314 We initially anticipated that the phenotypes of *Seh1*$^{-/-}$ mESCs could be caused by a
315 combination of its functions within the Y- and the GATOR2-complexes. However, the
316 fact that the *Mios*$^{-/-}$ cells do not feature any NPC assembly, nuclear size, or cell

317 differentiation defects rather suggests that *Seh1*$^{-/-}$ phenotypes (except perhaps a
318 mild contribution to cell growth rates) are unlikely to result from a combination of
319 defects in NPC and GATOR function. Moreover, *Nup43*$^{-/-}$ mESC phenotypes are very
320 similar to those of *Seh1*$^{-/-}$ mESCs, despite the fact that Nup43 does not interact with
321 Mios.

322 Our data also showed that integrity of the short arm of the Y-complex is important
323 for proper NPC density, further distinguishing its function from that of Nup133,
324 which specifically affects NPC basket assembly in mESCs (Souquet et al., 2018). The
325 observed reduction in NPC density in our *Seh1*$^{-/-}$, *Nup43*$^{-/-}$ and *ΔE2-GFP-Nup85* clones
326 likely reflects an absolute reduction in total NPC number, since there was no
327 corresponding increase in nuclear surface in these cells (instead, nuclear size was
328 mildly reduced in *Seh1*$^{-/-}$ mESCs). Different mechanisms may explain the requirement
329 for an intact short arm of the Y-complex to ensure proper NPC numbers. Considering
330 the critical roles of the Y-complex in both NPC re-assembly after mitosis and *de novo*
331 NPC assembly in interphase (Doucet et al., 2010; Harel et al., 2003; Walther et al.,
332 2003), the short arm of the Y-complex might be required for the efficient
333 recruitment of the Y-complex either to the mitotic chromatin (an hypothesis
334 consistent with the minor reduction of Y-complex levels on chromatin reported upon
335 Seh1 depletion in HCT116 cells - Platani et al., 2018), or to the nuclear envelope in
336 interphase (as process involving Nup153 Vollmer et al., 2015). Alternatively, Nup43
337 and Seh1 may contribute to the stabilization of the NPC scaffold, by virtue of their
338 direct interactions with neighbouring subunits from either Y-complexes or inner ring
339 complexes (Huang et al., 2020; Kosinski et al., 2016; von Appen et al., 2015). NPCs
340 lacking these stabilizing interactions might then be recognized by one of the recently
341 described quality-control mechanisms that mediate the removal of some
342 misassembled NPCs from the nuclear envelope (reviewed in Webster and Lusk,
343 2016).

344 Finally, our analysis of the *ΔE2-GFP-Nup85* cell lines indicates that the reduction in
345 NPC density observed in *Seh1*$^{-/-}$ and *Nup43*$^{-/-}$ mESCs is not sufficient to impact cell
346 growth and differentiation. The lack of major growth and differentiation defects in
347 *ΔE2-GFP-Nup85* cells, in which Seh1 is largely mislocalized from NPCs, could reflect

348 an “off-pore” function of Seh1, or a function of Seh1 that does not require its normal
349 stoichiometry within NPCs (for instance, a localization restricted to the cytoplasmic
350 or nuclear side of the NPCs). At NPCs, Seh1 and Nup43 might be required for the
351 proper recruitment and positioning of the mRNA export and remodelling machinery,
352 an established function of the short arm of the Y-complex in budding yeast
353 (Fernandez-Martinez et al., 2016). Alternatively, whether at pores or elsewhere in
354 the nucleus, Seh1 and Nup43 may impact cell growth and differentiation by directly
355 contributing to gene regulation, as now reported for a few Nups in mammalian cells
356 (reviewed in Buchwalter et al., 2019; Pascual-Garcia and Capelson, 2019; see also
357 Scholz et al., 2019). In particular, Seh1 was recently found to participate in
358 oligodendrocyte differentiation, acting as a platform to recruit transcription and
359 chromatin remodelling factors (Olig2 and Brd7) (Liu et al., 2019). We may
360 hypothesize that both Seh1 and Nup43 may specifically interact with factors
361 required for gene regulation and chromatin organization in mESCs, hence
362 contributing to early stages of pluripotent cell growth and differentiation.

363

363 ## Materials and Methods

364 **Plasmids** used in this study are listed in **Table S1**. They were either previously
365 published or generated using standard molecular cloning techniques including
366 restriction digestions (Fastdigest, Thermo Fisher Scientific, Waltham, MA), PCR
367 amplification using proofreading DNA polymerases (Phusion HF, New England Biolab,
368 Ipswich, MA) and In-Fusion HD Cloning Kit (Clontech, Mountain View, CA) or
369 NEBuilder HiFi DNA Assembly Cloning Kits (New England Biolab). The *Mios* and
370 *Nup43* gRNAs were integrated in a linear plasmid (GeneArt™ CRISPR Nuclease Vector
371 – OFP-Cas9) following manufacturer´s instructions. The other Cas9 vectors (pX-280,
372 pX-672, pX-853 and pX-864) were assembled by golden gate cloning (Engler et al.,
373 2009). For all constructs, PCR-amplified fragments and junctions were checked by
374 sequencing. Plasmid maps are available upon request.

375

376 **Cell lines, growth condition, transfection, and CRISPR/CAs9-based genome editing**
377 Cell lines used in this study are listed in **Table S2**. All cells were grown at 37°C and 5%
378 CO_2.
379 DR4-mouse embryonic fibroblast feeder cells, DR4-MEFs (Applied StemCells), were
380 grown in Dulbecco's Modified Eagle's Medium (DMEM) (Gibco/Thermofisher)
381 supplemented with 15% heat-inactivated foetal bovine serum (FBS, Gibco), 100U/ml
382 Penicillin-100µg/ml Streptomycin (P/S) (Gibco) and 2mM L-Glutamine (Gibco). DR4-
383 MEFs were inactivated using 8.5 µg/ml Mitomycin-C (Sigma-Aldrich, St Louis, MO) for
384 3 hours.
385 HM1 (Selfridge et al., 1992) and derivative mESCs clones were grown in
386 serum/leukemia inhibitory factor (LIF)-containing stem cell medium: DMEM
387 (EmbryoMax, Millipore, Burlington, MA), P/S (Gibco), 2mM L-Glutamine (Gibco), 15%
388 heat-inactivated ESC-Qualified FBS (Gibco), non-essential amino acids (Gibco),
389 nucleosides (Millipore), 2-mercaptoethanol (Gibco) and 10^3 units/ml LIF (ESGRO,
390 Millipore). mESCs were grown on inactivated DR4-MEFs (MEF-derived feeders)
391 plated on 0.1% gelatin (Sigma-Aldrich) and were passaged every 2 or 3 days using
392 0.05% Trypsin (Gibco). mESCs were used at passages below 30. Lack of
393 contamination in-between the mutant cell lines was assessed by PCR on genomic

394 DNA, proper GFP-or mCherry expression when pertinent, and western blots
395 analyses. Frequent DAPI staining ensured lack of major contamination by
396 mycoplasm. When required, cells were counted using a Countess automated cell
397 counter (Invitrogen, Carlsbad, CA).
398 For transfections, mESCs were plated onto DR4-MEFs in medium without P/S.
399 Plasmid DNA and Lipofectamine 2000 (Invitrogen) were mixed in OptiMEM
400 (Invitrogen) and added to the cells according to the manufacturer's instructions.

401 For CRISPR/Cas9 editing, $5 \cdot 10^5$ mESCs were transfected as indicated in **Table S2** with
402 one or two plasmids (3µg each) directing the expression of one or two gRNAs along
403 with Cas9 (WT or high fidelity, HF) fused to GFP, mCherry or OFP. gRNAs were
404 designed using the Benchling website (https://benchling.com) and are listed in **Table**
405 **S3**. When indicated, DNA sequences of interest (PCR product 1-4 µg, or 3µg of
406 linearized plasmid) flanked by homology directed repair arms were co-transfected
407 **(Fig. S4)**. Following selection (as detailed below), individual clones were picked,
408 amplified, and further characterized. For each clone, chromosome spreads were also
409 performed (chromosome counts are indicated in **Table S2**).

410 To establish *Seh1*$^{-/-}$, *Mios*$^{-/-}$ and *Nup43*$^{-/-}$ cell lines, cells were collected by
411 trypsinization two days after transfection, resuspended in 1 mL Fluorescence-
412 activated cell sorting (FACS) buffer (PBS +10% FBS, Gibco + P/S), and sorted based on
413 Cas9 expression (EGFP or OFP signal). 2000 FACS-sorted cells were plated in 100mm
414 culture dishes. Individual clones picked 6-12 days after sorting were then
415 characterized using Western blot and PCR on genomic DNA followed by sequencing
416 (the identified Indels are listed in **Table S2**).

417 To establish the *OsTir* cell line, 200µg/mL Geneticin (Geneticin® Gibco, Life
418 technologies 10131-019) was added to the medium two days after transfection.
419 Geneticin-resistant clones (expected to have integrated the pCAG-OsTir-T2A-NeoR
420 sequence at the *Tigre* locus) were picked after five days and characterized by
421 Western-blot with antibodies directed against the OsTir receptor. PCR on genomic
422 DNA was also performed to determine the number of *Tigre* alleles bearing the
423 transgene.

424 To generate the *Seh1 rescue* (expressing GFP-Seh1 under the pCAG promoter at the
425 *Tigre* locus), *GFP-Seh1*, *GFP-mAID-Seh1*, *ΔE2-GFP-Nup85* and [*ΔE2-mCherry-Nup85*]
426 cell lines, GFP [mCherry] positive cells were FACS-sorted 3 days after transfection to
427 select for cells expressing the tagged nucleoporin. Individual clones were picked 6-7
428 days after sorting and characterized using immunofluorescence (to confirm the
429 localization of the tagged protein at the nuclear periphery) and western blot (to
430 identify clones lacking the endogenous protein). The selected clones were then
431 further validated by PCR on genomic DNA and sequencing.

432 To achieve inducible degradation of GFP-mAID-Seh1, Auxin (Sigma-Aldrich) was
433 added to the medium at 500µM (from a stock at 280 mM in EtOH). For control
434 experiments, the same amount of EtOH was added.

435

436 **Cell growth and differentiation assays**

437 To evaluate cell growth at pluripotent stage, cells were plated at 1 - $2{\cdot}10^5$ cells per
438 well in TPP 12-well plate. Photomicrographs were taken every two hours using an
439 IncuCyte® live cell imager (Essen Biosciences, Ann Arbor, MI) and confluence of the
440 cultures was measured using IncuCyte® software (Essen Biosciences, Ann Arbor,
441 MI). To improve comparison in-between experiments or cell lines, the same mask
442 was always used and time was set at t=0 when confluence reached 1% (**Figs. 1D and**
443 **6C**), 2% (**Fig. 5C**) or 3% (**Fig. S1E**). Graphs were generated using Excel. Error bars
444 correspond to standard deviations from the indicated [n=] independent
445 experiments.

446

447 Neuroectodermal differentiation of mESCs grown as monolayers was adapted from
448 (Ying and Smith, 2003). Following trypsinization, feeders were removed by plating
449 the resuspended cells in gelatin-free wells for 20 minutes. Feeder-free mESCs were
450 collected and resuspended in N2B27 medium [DMEM F-12, DMEM Neurobasal, BSA,
451 L-glutamin, 2-mercaptoethanol, N2 (Gibco) and B27 (Gibco)]. Cells were plated in
452 gelatin-coated wells at $1{\cdot}10^5$ or $3{\cdot}10^4$ cells per well in TPP 12 well plate. At day 2,
453 N2B27 medium containing 1µM RA (all-trans-Retinoic acid, Sigma) was added for 24
454 hours. From day 3 to 7 medium was changed every day with fresh N2B27 without

455 RA. Confluence analyses, used as a proxy to evaluate cell growth and viability, was
456 performed as described above except that time was set at t=0 the beginning of the
457 differentiation process (i.e., upon plating in N2B27 medium).
458
459 **Fluorescence Videomicroscopy**
460 mESCs were transiently transfected using plasmids expressing H2B-GFP or H2B-
461 mCherry on microscopy-adapted 35-mm dishes (µ-dish, 35 mm, high; Ibidi,
462 Germany) coated with 0.1% gelatin and DR4-MEFs. Acquisitions were performed
463 about 36 hours after transfection at 37ºC and 5% of CO_2 using an AxioObserverZ1
464 inverted microscope (Zeiss, Germany) equipped with a 63 oil objective, a CSU-X1
465 spinning-disk head (Yokogawa, Japan), and a sCMOSPRIME 95B (Photometrics)
466 camera.
467 The whole setup was driven with MetaMorph software (Molecular Devices,
468 Sunnyvale, CA). Eleven Z sections with a step of 1µm were acquired at intervals of 5
469 minutes for the mitotic progression experiments (4-6 hours) and of 15 minutes for
470 the cell cycle length experiments (24-30 hours). Laser intensity was set between 10-
471 20% power and acquisition time was 500ms. The raw data were processed using
472 ImageJ software (National Institutes of Health, Bethesda, MD). Images stacks were
473 processed as max projections. Cells were tracked manually setting prometaphase at
474 the moment at which chromatin starts to be seen condensed and anaphase at the
475 first time point at which chromosome segregation is observed.
476
477 **FACS analyses**
478 To perform a bi-parametric analysis of cell cycle based on DNA content (DAPI) and
479 DNA synthesys (EdU) we used the Click-it-EdU Imaging kits (Invitrogen). 0.5 10^6 mESC
480 were plated on MEF-derived feeders plated on 0.1% gelatin 2 days before the
481 experiment. Cells were incubated with EdU 50 µm for 15 minutes, then collected by
482 trypsinyzation and plated on gelatin dishes for 20 minutes to remove feeders.
483 Cells were then collected and centrifuged, washed in PBS and then fixed in PFA 3%
484 for 15 minutes. Cells were then permeabilized with PBS+ 0.2% Triton-X100 and
485 washed with PBS + 2% SVF. Click reaction (30 minutes) was performed following
486 manufacturer's protocol. DNA was stained for 20 minutes (DAPI 5 µM, RNaseA 0.1

487 mg/mL, 1% SVF in PBS), then samples were centrifuged and resuspended in 60µl PBS
488 +2% SVF.
489 Sample acquisition was achieved with the ImageStream® X (Amnis, Austin, TX)
490 imaging flow cytometer and captured using the ISX INSPIRE™data acquisition
491 software. Images of 5.000–20.000 cells were acquired at 40x magnification using the
492 following channels: Ch1= 430-470 nm, BF (bright field); Ch6= 720-800nm, SS (side
493 scatter); Ch7= 430-505 nm, DAPI; Ch9= 570-595, BF; Ch11= 660-720 nm, EdU-AF647.
494 A compensation matrix was generated using fluorescence controls and applied to all
495 samples. Analysis was then performed with the IDEAS software as follows: 1)
496 definition of cells in focus, based on the gradient RMS; 2) definition of singlets,
497 according to area and aspect ratio; 3) definition of cells using contrast and gradient
498 RMS; 4) definition of nucleated cells using DNA content; 5) cell cycle phases were
499 then identified using DAPI and EdU intensity; 6) mitotic cells were finally defined
500 according to DAPI bright detail intensity and DAPI area threshold (**Fig. S2 D**).

501

502 **Immunostaining and quantitative image analyses**

503 mESCs grown on coverslips were washed with PBS, then fixed using 3% para-
504 formaldehyde (VWR, Radnor, PA) for 20 min and washed again with PBS. For all
505 conditions, cells were then permeabilized in PBS + 0.2% Triton X-100, 0.02% SDS
506 (Euromedex, Souffelweyersheim, FR), and 10 mg/mL BSA (Sigma). Antibody
507 hybridizations and washes were also performed in this buffer. Primary and
508 secondary antibodies (listed in **Table S4**) were incubated for 1 hr at room
509 temperature. Cells were then incubated 5 min with 280nM DAPI (Sigma) in PBS and
510 mounted with Vectashield (Vector, Maravai Life Sciences, San Diego, CA). Images
511 were acquired using 100x/1.4 oil objectives on inverted and motorized microscopes,
512 either a DMI8 (Leica), equipped with a CSU-W1 spinning-diskhead (Yokogawa, Japan)
513 and 2 Orca-Flash 4 V2+ sCMOS cameras (Hamamatsu), or an Axio Observer.Z1
514 (Zeiss), equipped with CSU-X1 spinning-diskhead (Yokogawa, Japan) and 2 sCMOS
515 PRIME 95 cameras (Photometrics).

516 <u>Quantification of NPC density</u> at the nuclear envelope (NE) was performed
517 essentially as described (Souquet et al., 2018). Briefly, mESCs of interest were mixed

518 with a GFP cell line of reference (*Rescue-Seh1* or *ΔE2-GFP-Nup85* cells, used for
519 normalization) and grown on coverslips for 24h prior to fixation and immunostaining.
520 For each acquired image, one z section was selected; 8-pixel-thick regions of interest
521 (ROIs) were drawn freehand on the NE of both GFP-negative and -positive
522 (reference) mESCs. Following subtraction of background, the signal intensity at the
523 NE for each cell was normalized to the average NE intensity measured for the GFP-
524 positive mESCs acquired in the same field. All values were then divided by the mean
525 normalized intensity of *WT* mESCs acquired in the same experiment. Box plots were
526 generated using GraphPad Software: each box encloses 50% of the normalized
527 values obtained, centred on the median value. The bars extend from the 5th to 95th
528 percentiles. Values falling outside of this range are displayed as individual points.
529 For kinetochore quantifications, mixed *GFP-Seh1* and *ΔE2-mCherry-Nup85/GFP-Seh1*
530 mESCs grown on coverslips were fixed, permeabilized, and stained with DAPI. Fields
531 containing both *GFP-Seh1* and *ΔE2-mCherry-Nup85/GFP-Seh1* mitotic cells were
532 selected. For each mitotic cell, the mean intensities of five distinct kinetochores
533 (regions of 10-pixels in diameter) and of two "background" regions in the mitotic
534 cytoplasm (40-pixels in diameter) were measured on a unique z-section. Following
535 background subtraction, the average intensity of GFP-Seh1 at kinetochores in each
536 mitotic cell was normalized to the intensity measured for the control (*wtNup85/*
537 *GFP-Seh1*) mitotic cells acquired in the same experiment. Box plots were generated
538 as described above.
539
540 To quantify nuclear surfaces, mESCs of interest were mixed with a GFP cell line of
541 reference and grown on coverslips for 24 hr prior to fixation and immunostaining as
542 described above. For each field, 33 to 45 optical sections (0.5 µm apart) were
543 acquired and nuclei were segmented based on TPR immunostaining with the Fiji
544 plugin Lime-Seg (Machado et al., 2019). A circular ROI was drawn within the nucleus
545 of each cell in the field and the LimeSeg Plugin “Sphere Seg advanced” was run with
546 the following parameters: D0: 4; Zscale: 7.143; range in D0 units: 2; real xy pixel size:
547 0.07; F pressure: 0.025 for TPR-Cy3 staining and 0.019 for TPR-Cy5. Segmented
548 structures for which the “free edges” values were above 0 (segmentation could not
549 close the structure), and those for which the Euler characteristic was not comprised

550 between -4/+4 (aberrant structures very far from a spherical shape) were discarded.
551 For each cell, the segmentation perimeter and TPR staining along the z-axis were
552 compared to further validate proper segmentation (less than 8% of the identified
553 structures, frequently corresponding to the merge of two closely apposed nuclei,
554 were manually discarded at that stage). Nuclear surfaces and volumes were then
555 exported. To compensate for variability occurring during fixation or IF processing,
556 nuclear surface values were first normalized to the average of the GFP-reference
557 cells acquired within the same coverslip, and then to the mean of *WT* mESCs
558 acquired in the same experiment. Nuclear surface graphs were generated using
559 GraphPad Software: average and standard deviation (boxes and bars) of nuclear
560 surface are displayed, along with values for each experiment (dots).
561
562 **Western blot analyses**
563 To prepare whole cell lysates, mESCs were lysed in 2× Laemmli lysis buffer (150-mM
564 Tris-HCL (pH 6.8), 5 % (wt/vol) SDS, 25 % (vol/vol) glycerol, and 0.01 % (wt/vol)
565 bromophenol blue). Lysates were incubated for 3 min at 95 °C, clarified by sonication
566 (Bioruptordiagenode: 4 cycles of 30 s on/off, high power), and denatured again for 3
567 min at 95°C. Protein concentration was then determined using a BCA assay kit
568 (Thermo Fisher Scientific). Total protein extracts supplemented with β-
569 mercaptoethanol (750 mM final, Sigma-Aldrich) were analysed by western blot. 10
570 µg of mESC lysate were separated on 4–12% or 10% SDS-PAGE gels (pre-cast
571 NuPage® GE healthcare or Mini-Protean TGX Stain free precast gels, Biorad,
572 Hercules, CA) and transferred to nitrocellulose (GE healthcare). The resulting blots
573 were stained using Ponceau, saturated with TBS buffer + 0.1% Tween and 5% dried
574 milk, and incubated in TBS + 0.1% Tween and 5% dried milk with primary antibodies,
575 followed by either HRP-conjugated secondary antibodies of interest or HRP-
576 conjugated anti-rabbit TrueBlot® secondary antibody (used in **Fig. 5B** to prevent
577 interference from the denatured/reduced heavy and light chains of the anti-Seh1
578 antibody used for immunoprecipitation (primary and secondary antibodies are listed
579 in **Table S4**). Signals were detected by enhanced chemiluminescence (SuperSignal®
580 Pico or Femto, ThermoScientific) using ChemiDoc (Biorad).
581

582 **Immunoprecipitation experiments and mass spectrometry analyses**

583 Immunoprecipitation experiments: Protein G beads (GE Helathcare) were washed
584 three times with Wash buffer (100mM NaCl, 1mM EDTA, 25mM TRIS pH 7.5, 1mM
585 DTT + protease inhibitor [Pi] solution); (bead centrifugations were performed at 500g
586 4°C). 30µL of beads were then incubated for 2 hours at 4°C in 250µL wash buffer
587 containing 5µL of rabbit anti-Seh1 antibody (for **Fig. 5B**), or 25µL of rabbit polyclonal
588 anti-Nup107 or anti-Nup85 serum or a pre-immune rabbit serum as control (for **Fig.**
589 **S3B**). Antibodies used are listed in **Table S4**. After incubation, beads were washed 4
590 times with Wash buffer.

591 In the meantime, lysates were prepared from *WT, Seh1*$^{-/-}$, *Mios*$^{-/-}$ or *ΔE2-GFP-Nup85*
592 mESCs by resuspending frozen pellets of $4{\cdot}10^6$ mESCs (~500µg total proteins) in
593 200µl Lysis buffer (100mM NaCl, 1mM EDTA, 25mM TRIS pH 7.5, 1mM DTT, Tween-
594 20 0.5%, Triton-100 1.2% + PI solution). Samples were vortexed and incubated 15
595 min on ice. 600µL of Dilution buffer (100mM NaCl, 1mM EDTA, 25mM TRIS pH 7.5,
596 1mM DTT, Tween-20 0.5%, + PI solution) was then added and samples were
597 centrifuged at 16.000 g for 30 min at 4°C. The resulting supernatant was pre-cleared
598 by a 1 hour incubation at 4°C with 30µL Protein G beads equilibrated with wash
599 buffer.

600 The cleared supernatants (inputs) were then incubated at 4°C with 30µL of the anti-
601 Seh1, control, anti-Nup107- or anti-Nup85-coated Protein G beads. After overnight
602 (for anti-Seh1) or 2 hours incubation (for anti-Nup107 and anti-Nup85), samples
603 were centrifuged and washed 5 times in wash buffer. The proteins were either
604 eluted in 40µL of Laemmli and boiled 10 minutes for subsequent western blot
605 analysis (**Fig. 5B**), or split in 2 and then either eluted in 20µL of Laemmli and boiled 3
606 minutes for subsequent western blot analyses, or processed for both mass-
607 spectrometry and western blot analyses (for experiments presented in **Fig. S3**).

608 Samples preparation prior to LC-MS/MS analysis: Proteins on beads were digested
609 overnight at 37°C with trypsin (Promega, Madison, WI, USA) in a 25-mM NH_4HCO_3
610 buffer (0.2µg trypsin in 20µL). The resulting peptides were desalted using ZipTip µ-
611 C18 Pipette Tips (Pierce Biotechnology, Rockford, IL, USA).

612 **LC-MS/MS acquisition:**

613 Samples were analyzed using an Orbitrap Fusion, coupled to a Nano-LC Proxeon
614 1200, equipped with an easy spray ion source (Thermo Scientific, Waltham, MA,
615 USA). Peptides were loaded with an online preconcentration method and separated
616 by chromatography using a Pepmap-RSLC C18 column (0.75 x 750 mm, 2 µm, 100 Å)
617 from Thermo Scientific, equilibrated at 50°C and operated at a flow rate of 300
618 nl/min. Solvents (MS grade H_2O, formic acid (FA) and Acetonitrile (ACN)) were from
619 Thermo Chemical (Waltham, MA, USA).

620 Peptides were eluted by a gradient of solvent A (H_2O, 0.1 % FA) and solvent B
621 (ACN/H_2O 80/20, 0.1% FA). The column was first equilibrated 5 min with 95 % of
622 solvent A, then solvent B was raised to 28 % in 105 min and to 40% in 15 min. Finally,
623 the column was washed with 95% solvent B during 20 min and re-equilibrated at
624 95% solvent A during 10 min. On the Orbitrap Fusion instrument, peptides precursor
625 masses were analyzed in the Orbitrap cell in full ion scan mode, at a resolution of
626 120,000, a mass range of *m/z* 350-1550 and an AGC target of 4.10^5. MS/MS were
627 performed in the top speed 3s mode. Peptides were selected for fragmentation by
628 Higher-energy C-trap Dissociation (HCD) with a Normalized Collisional Energy of 27%
629 and a dynamic exclusion of 60 seconds. Fragment masses were measured in an Ion
630 trap in the rapid mode, with and an AGC target of 1.10^4. Monocharged peptides and
631 unassigned charge states were excluded from the MS/MS acquisition. The maximum
632 ion accumulation times were set to 100 ms for MS and 35 ms for MS/MS acquisitions
633 respectively.

634 <u>Data analysis:</u> Raw data were processed on Proteome Discoverer 2.2 with the
635 mascot node (Mascot version 2.5.1) and the Swissprot protein database release
636 2017_06. The *Mus musculus* taxonomy was used and a maximum of 2 missed
637 cleavages was authorized. Precursor and fragment mass tolerances were set to 7
638 ppm and 0.5 Da. The following Post-translational modifications were included as
639 variable: Acetyl (Protein N-term), Oxidation (M), Phosphorylation (STY). Spectra were
640 filtered using a 1% FDR with the percolator node.

641

642 **Statistics**

643 For cell confluence analyses, statistical analyses were performed at the latest time
644 points (48h for cell growth in the pluripotent state and day 5 for neuroectodermal
645 differentiation) using paired two-tailed Student's t-test. For each mutant cell line,
646 the % of confluence was compared to that of *WT* cells measured in the same
647 experiment. To obtain more robust statistics, the paired two-tailed Student's t-test
648 was also used to compare all the values obtained with distinct clones bearing the
649 same mutation to *WT* cells. For studies of interphase and mitosis duration and for
650 quantifications of fluorescence intensity at the NE, statistical analyses were
651 performed using unpaired non-parametric Mann-Whitney test. For nuclear surfaces,
652 statistical analyses were performed using paired two-tailed Student's t-test. P values
653 and significance: ****: P <0.0001; ***: P <0.001; **: P <0.01; * :P <0.05.

654

655 **DATA AND SOFTWARE AVAILABILITY**

656 The mass spectrometry proteomics data reported in this study have been deposited
657 to the ProteomeXchange Consortium
658 (http://proteomecentral.proteomexchange.org) via the PRIDE partner repository
659 (Perez-Riverol et al., 2019) with the dataset identifier PXD022190.

660

661 The original 16-bit images and montages of the western blots used in this study
662 are available as Mendeley dataset under http://dx.doi.org/10.17632/8g59mp92bs.1

663

664

665

Acknowledgments

We are grateful to V. Heyer for generating the CRISPR/Cas9 vectors, to B. Souquet and A. Berto for advices regarding mESCs culture, and to P. Navarro and N. Festuccia for advices and reagents regarding integration at the *Tigre* locus and degron approaches. We kindly thank Jan Kosinski for discussions about the Nup85-Seh1 model, D. Forbes for sharing the Nup85 antibodies, N. Minc and S. Dmitrieff for their advices in the analysis of nuclear size, Liang Zhang for advise regarding anti-Seh1 immunoprecipitation experiments, and C. Boumendil and R. Karess for critical reading of the manuscript. We thank the proteomics core facility at the Institut Jacques-Monod, notably C. Garcia and L. Lignières, for the LC-MS/MS experiments. We also acknowledge the ImagoSeine core facility of the Institut Jacques Monod, notably M. Fradet and X. Baudin for help with cell sorting and spinning disk imaging, respectively.

Competing interests

No competing interests declared.

Funding

Work in the laboratory of VD was supported by the Centre national de la recherche scientifique (CNRS), the "Fondation pour la Recherche Médicale" (Foundation for Medical Research) under grant No DEQ20150734355, "Equipe FRM 2015" to VD and by the Labex Who Am I? (ANR-11-LABX-0071; Idex ANR-11-IDEX-0005-02). AG received a PhD fellowship from the INSPIRE, H2020-MSCA-COFUND-2014, Marie Skłodowska-Curie Co-funding of regional, national and international programmes, grant agreement No 665850, and a "transition post-doc grant from the Labex Who Am I?, AV received a post-doc grant from the Labex Who Am I? and CO a fellowship from Ecole Doctorale BioSPC, Université de Paris. Part of the LC-MS/MS equipment was founded by the Region Ile-de-France (SESAME 2013 Q-Prot-B&M - LS093471), the Paris-Diderot University (ARS 2014-2018), and CNRS (Moyens d'Equipement Exceptionnel INSB 2015). The ImagoSeine core facility was supported by founds from IBISA and the France-Bioimaging (ANR-10-INBS-04) infrastructures.

696 **AUTHOR CONTRIBUTIONS**

697 A.G-E., A.V., C.O., B.R-S-M., and V.D. conceived and designed the experiments.
698 A.G-E., A.V., and C.O. performed the experiments. A.G-E., A.V., C.O., and V.D.
699 analyzed the data. A.G-E., A.V., and V.D. wrote the manuscript with contribution
700 from all co-authors.

701

701 ## References

702

703 **Algret, R., Fernandez-Martinez, J., Shi, Y., Kim, S.J., Pellarin, R., Cimermancic, P.,**
704 **Cochet, E., Sali, A., Chait, B.T., Rout, M.P.*, et al.*** (2014). Molecular Architecture and
705 Function of the SEA Complex, a Modulator of the TORC1 Pathway. *Mol Cell*
706 *Proteomics* **13**, 2855-2870.

707 **Bar-Peled, L., Chantranupong, L., Cherniack, A.D., Chen, W.W., Ottina, K.A.,**
708 **Grabiner, B.C., Spear, E.D., Carter, S.L., Meyerson, M., and Sabatini, D.M.** (2013). A
709 Tumor suppressor complex with GAP activity for the Rag GTPases that signal amino
710 acid sufficiency to mTORC1. *Science* **340**, 1100-1106.

711 **Brohawn, S.G., Leksa, N.C., Spear, E.D., Rajashankar, K.R., and Schwartz, T.U.**
712 (2008). Structural Evidence for Common Ancestry of the Nuclear Pore Complex and
713 Vesicle Coats. *Science* **322**, 1369-1373.

714 **Buchwalter, A., Kaneshiro, J.M., and Hetzer, M.W.** (2019). Coaching from the
715 sidelines: the nuclear periphery in genome regulation. *Nat Rev Genet* **20**, 39-50.

716 **Cai, W., Wei, Y., Jarnik, M., Reich, J., and Lilly, M.A.** (2016). The GATOR2
717 Component Wdr24 Regulates TORC1 Activity and Lysosome Function. *PLoS Genet* **12**,
718 e1006036.

719 **Debler, E.W., Ma, Y., Seo, H.S., Hsia, K.C., Noriega, T.R., Blobel, G., and Hoelz, A.**
720 (2008). A Fence-like Coat for the Nuclear Pore Membrane. *Mol Cell* **32**, 815-826.

721 **Dokudovskaya, S., and Rout, M.P.** (2015). SEA you later alli-GATOR - a dynamic
722 regulator of the TORC1 stress response pathway. *J Cell Sci* **128**, 2219-2228.

723 **Doucet, C.M., Talamas, J.A., and Hetzer, M.W.** (2010). Cell cycle-dependent
724 differences in nuclear pore complex assembly in metazoa. *Cell 141*, 1030-1041.

725 **Faria, A.M.C., Levay, A., Wang, Y., Kamphorst, A.O., Rosa, M.L.P., Nussenzveig,**
726 **D.R., Balkan, W., Chook, Y.M., Levy, D.E., and Fontoura, B.M.A.** (2006). The
727 Nucleoporin Nup96 Is Required for Proper Expression of Interferon-Regulated
728 Proteins and Functions. *Immunity* **24**, 295-304.

729 **Engler, C., Gruetzner, R., Kandzia, R., and Marillonnet, S.** (2009). Golden Gate
730 Shuffling: A One-Pot DNA Shuffling Method Based on Type IIs Restriction Enzymes.
731 *PLOS ONE* **4**, e5553.

732 **Fernandez-Martinez, J., Kim, S.J., Shi, Y., Upla, P., Pellarin, R., Gagnon, M.,**
733 **Chemmama, I.E., Wang, J., Nudelman, I., Zhang, W.*, et al.*** (2016). Structure and
734 Function of the Nuclear Pore Complex Cytoplasmic mRNA Export Platform. *Cell* **167**,
735 1215-1228.e1225.

736 **Hampoelz, B., Andres-Pons, A., Kastritis, P., and Beck, M.** (2019). Structure and
737 Assembly of the Nuclear Pore Complex. *Annu Rev Biophys* **48**, 515-536.

738 **Harel, A., Orjalo, A.V., Vincent, T., Lachish-Zalait, A., Vasu, S., Shah, S., Zimmerman,**
739 **E., Elbaum, M., and Forbes, D.J.** (2003). Removal of a single pore subcomplex results
740 in vertebrate nuclei devoid of nuclear pores. *Mol Cell* **11**, 853-864.

741 **Hezwani, M., and Fahrenkrog, B.** (2017). The functional versatility of the nuclear
742 pore complex proteins. *Semin Cell Dev Biol* **68**, 2-9.

743 **Huang, G., Zhang, Y., Zhu, X., Zeng, C., Wang, Q., Zhou, Q., Tao, Q., Liu, M., Lei, J.,**
744 **Yan, C., and Shi, Y.**(2020). Structure of the cytoplasmic ring of the Xenopus laevis
745 nuclear pore complex by cryo-electron microscopy single particle analysis. *Cell Res*
746 **30**,520-531

747 **Jevtić, P., Mukherjee, R.N., Chen, P., and Levy, D.L.** (2019). Altering the levels of
748 nuclear import factors in early Xenopus laevis embryos affects later development.
749 *PLoS ONE* **14**, e0215740.

750 **Kosinski, J., Mosalaganti, S., von Appen, A., Teimer, R., DiGuilio, A.L., Wan, W., Bui,**
751 **K.H., Hagen, W.J.H., Briggs, J.A.G., Glavy, J.S.*, et al.*** (2016). Molecular architecture
752 of the inner ring scaffold of the human nuclear pore complex. *Science* **352**, 363-365.

753 **Lin, D.H., and Hoelz, A.** (2019). The Structure of the Nuclear Pore Complex (An
754 Update). *Annu Rev Biochem* **88**, 725-783.

755 **Liu, Z., Yan, M., Liang, Y., Liu, M., Zhang, K., Shao, D., Jiang, R., Li, L., Wang, C.,**
756 **Nussenzveig, D.R.*, et al.*** (2019). Nucleoporin Seh1 Interacts with Olig2/Brd7 to
757 Promote Oligodendrocyte Differentiation and Myelination. *Neuron* **102**, 587-601.e7

758 **Loiodice, I., Alves, A., Rabut, G., Van Overbeek, M., Ellenberg, J., Sibarita, J.B., and**
759 **Doye, V.** (2004). The entire Nup107-160 complex, including three new members, is
760 targeted as one entity to kinetochores in mitosis. *Mol Biol Cell* **15**, 3333-3344.

761 **Lupu, F., Alves, A., Anderson, K., Doye, V., and Lacy, E.** (2008). Nuclear pore
762 composition regulates neural stem/progenitor cell differentiation in the mouse
763 embryo. *Dev Cell* **14**, 831-842.

764 **Machado, S., Mercier, V., and Chiaruttini, N.** (2019). LimeSeg: a coarse-grained lipid
765 membrane simulation for 3D image segmentation. *BMC bioinformatics* **20**, 2.

766 **Moreira, T.G., Zhang, L., Shaulov, L., Harel, A., Kuss, S.K., Williams, J., Shelton, J.,**
767 **Somatilaka, B., Seemann, J., Yang, J.*, et al.*** (2015). Sec13 Regulates Expression of
768 Specific Immune Factors Involved in Inflammation In Vivo. *Sci Rep* **5**, 17655.

769 **Natsume, T., Kiyomitsu, T., Saga, Y., and Kanemaki, M.T.** (2016). Rapid Protein
770 Depletion in Human Cells by Auxin-Inducible Degron Tagging with Short Homology
771 Donors. *Cell Rep* **15**, 210-218.

772 **Neumann, N., Lundin, D., and Poole, A.M.** (2010). Comparative Genomic Evidence
773 for a Complete Nuclear Pore Complex in the Last Eukaryotic Common Ancestor. *PLoS*
774 *ONE* **5**, e13241.

775 **Okita, K., Kiyonari, H., Nobuhisa, I., Kimura, N., Aizawa, S., and Taga, T.** (2004).
776 Targeted disruption of the mouse ELYS gene results in embryonic death at peri-
777 implantation development. *Genes Cells* **9**, 1083-1091.

778 **Pascual-Garcia, P., and Capelson, M.** (2019). Nuclear pores in genome architecture
779 and enhancer function. *Curr Opin Cell Biol* **58**, 126-133.

780 **Perez-Riverol, Y., Csordas, A., Bai, J., Bernal-Llinares, M., Hewapathirana, S.,**
781 **Kundu, D.J., Inuganti, A., Griss, J., Mayer, G., Eisenacher, M.*, et al.*** (2019). The

782 PRIDE database and related tools and resources in 2019: improving support for
783 quantification data. *Nucleic Acids Res* **47**, D442-D450.

784 **Platani, M., Samejima, I., Samejima, K., Kanemaki, M.T., and Earnshaw, W.C.**
785 (2018). Seh1 targets GATOR2 and Nup153 to mitotic chromosomes. *J Cell Sci* **131**,
786 jcs213140.

787 **Platani, M., Santarella-Mellwig, R., Posch, M., Walczak, R., Swedlow, J.R., and**
788 **Mattaj, I.W.** (2009). The Nup107-160 nucleoporin complex promotes mitotic events
789 via control of the localization state of the chromosome passenger complex. *Mol Biol*
790 *Cell* **20**, 5260-5275.

791 **Platani, M., Trinkle-Mulcahy, L., Porter, M., Jeyaprakash, A.A., and Earnshaw, W.C.**
792 (2015). Mio depletion links mTOR regulation to Aurora A and Plk1 activation at
793 mitotic centrosomes. *J Cell Biol.* **210**, 45-62.

794 **Rabut, G., Doye, V., and Ellenberg, J.** (2004). Mapping the dynamic organization of
795 the nuclear pore complex inside single living cells. *Nat Cell Biol* **6**, 1114-1121.

796 **Rasala, B.A., Orjalo, A.V., Shen, Z.X., Briggs, S., and Forbes, D.J.** (2006). ELYS is a
797 dual nucleoporin/kinetochore protein required for nuclear pore assembly and
798 proper cell division. Proc Natl Acad Sci USA **103**, 17801-17806.

799 **Salama, N.R., Yeung, T., and Schekman, R.W.** (1993). The Sec13p Complex and
800 Reconstitution of Vesicle Budding from the Er with Purified Cytosolic Proteins. *EMBO*
801 *J* **12**, 4073-4082.

802 **Scholz, B.A., Sumida, N., de Lima, C.D.M., Chachoua, I., Martino, M., Tzelepis, I.,**
803 **Nikoshkov, A., Zhao, H.L., Mehmood, R., Sifakis, E.G.*, et al.*** (2019). WNT signaling
804 and AHCTF1 promote oncogenic MYC expression through super-enhancer-mediated
805 gene gating. *Nat Genet* **51**, 1723-1731.

806 **Selfridge, J., Pow, A.M., McWhir, J., Magin, T.M., and Melton, D.W.** (1992). Gene
807 targeting using a mouse HPRT minigene/HPRT-deficient embryonic stem cell system:
808 Inactivation of the mouseERCC-1 gene. *Somat Cell Molec Gen* **18**, 325-336.

809 **Senger, S., Csokmay, J., Tanveer, A., Jones, T.I., Sengupta, P., and Lilly, M.A.** (2011).
810 The nucleoporin Seh1 forms a complex with Mio and serves an essential tissue-
811 specific function in Drosophila oogenesis. *Development* **138**, 2133-2142.

812 **Souquet, B., Freed, E., Berto, A., Andric, V., Auduge, N., Reina-San-Martin, B., Lacy,**
813 **E., and Doye, V.** (2018). Nup133 Is Required for Proper Nuclear Pore Basket
814 Assembly and Dynamics in Embryonic Stem Cells. *Cell Rep* **23**, 2443-2454.

815 **Terashima, Y., Toda, E., Itakura, M., Otsuji, M., Yoshinaga, S., Okumura, K., Shand,**
816 **F.H.W., Komohara, Y., Takeda, M., Kokubo, K.*, et al.*** (2020). Targeting FROUNT with
817 disulfiram suppresses macrophage accumulation and its tumor-promoting
818 properties. *Nat Commun* **11**, 609.

819 **Vollmer, B., Lorenz, M., Moreno-Andrés, D., Bodenhöfer, M., De Magistris, P.,**
820 **Astrinidis, S.A., Schooley, A., Flötenmeyer, M., Leptihn, S., and Antonin, W.** (2015).
821 Nup153 Recruits the Nup107-160 Complex to the Inner Nuclear Membrane for
822 Interphasic Nuclear Pore Complex Assembly. *Dev Cell* **33**, 717-728.

823 **von Appen, A., Kosinski, J., Sparks, L., Ori, A., DiGuilio, A.L., Vollmer, B., Mackmull,**
824 **M.T., Banterle, N., Parca, L., Kastritis, P.*, et al.*** (2015). In situ structural analysis of
825 the human nuclear pore complex. *Nature* **526**, 140-143.

826 **Walther, T.C., Alves, A., Pickersgill, H., Loiodice, I., Hetzer, M., Galy, V., Hulsmann,**
827 **B.B., Kocher, T., Wilm, M., Allen, T.*, et al.*** (2003). The conserved Nup107-160
828 complex is critical for nuclear pore complex assembly. *Cell* **113**, 195-206.

829 **Webster, B.M., and Lusk, C.P.** (2016). Border safety: quality control at the nuclear
830 envelope. *Trends Cell Biol* **26**, 29-39.

831 **Ying, Q.L., and Smith, A.G**. (2003). Defined conditions for neural commitment and
832 differentiation. *Method Enzymol* **365**, 327-341

833 **Zeng, H., Horie, K., Madisen, L., Pavlova, M.N., Gragerova, G., Rohde, A.D.,**
834 **Schimpf, B.A., Liang, Y., Ojala, E., Kramer, F.*, et al*.** (2008). An inducible and
835 reversible mouse genetic rescue system. *PLoS genet* **4**, e1000069.

836 **Zuccolo, M., Alves, A., Galy, V., Bolhy, S., Formstecher, E., Racine, V., Sibarita, J.B.,**
837 **Fukagawa, T., Shiekhattar, R., Yen, T.*, et al.*** (2007). The human Nup107-160 nuclear
838 pore subcomplex contributes to proper kinetochore functions. *EMBO J* **26**, 1853-
839 1864.

840

840

841 **FIGURE AND FIGURE LEGENDS**

842 **Figure 1: Seh1 depletion leads to cell growth delay and impaired cell survival upon**
843 **differentiation.**

844 **A.** Schematic representation of the Y-complex (adapted from von Appen et al.,
845 2015), highlighting the components of the short arm, namely Nup43 (shown in
846 purple), Nup85 (blue) and Seh1 (red). ß-propellers are outlined with black strokes .**B.**
847 Western-blot showing the expression of endogenous or GFP-tagged Seh1, Nup107
848 and GAPDH (used as loading control) in whole cell extracts from the indicated cell
849 lines. 1/2 and 1/4 dilutions of *WT* extracts were also loaded. Molecular weights are
850 indicated (kilodaltons). **C.** Representative phase contrast images of *WT* and *Seh1*$^{-/-}$
851 (#1) mESCs colonies acquired after 2 days of growth on the IncuCyte® imager. Scale
852 bar, 300µm. **D-E.** Confluence of *WT* (blue), *Seh1*$^{-/-}$ (#1 and #2, red) and *Rescue* (#1
853 and #2, grey) mESCs was quantified with the IncuCyte® system either at pluripotent
854 stage (**D**) or upon differentiation towards neuroectodermal lineage (**E**). Error bars
855 correspond to the standard deviation arising from the indicated number of
856 independent experiments [n]. Statistical analyses of these confluence curves were
857 performed at the last time-points. Brackets indicate statistics performed using all
858 values from cell lines bearing a given mutation, compared to *WT* (see Materials and
859 Methods). **F.** Representative spinning disk images of *Rescue* (#1) mESCs showing
860 proper localization of GFP-Seh1 at the NE in interphase (one plane) and at
861 kinetochores in mitosis (a projection of 3 optical sections is presented). Scale bars,
862 10 µm.

863

864 **Figure 2: The altered growth rate of *Seh1*$^{-/-}$ mESCs reflects a lengthening**
865 **distributed over all phases of the cell cycle**

866 **A.** Quantification of interphase length of *WT* and *Seh1*$^{-/-}$ mESCs (2 distinct clones).
867 The black bars represent the median and each dot represent one individual cell. The
868 mean duration of interphase, as well as the number of imaged cells (N) and
869 experiments [n] is indicated **B.** Cell cycle profiles of *WT* and two *Seh1* $^{-/-}$ clones
870 generated by ImageStream® using the workflow analysis presented in **Fig. S2D**. For
871 each cell line, at least 3000 cells acquired in at least 3 distinct experiments were

872 analyzed.

873

874 **Figure 3: Quantification of NPC density in *Seh1* mutant cell lines.**

875 Normalized signal intensities at the NE of Nup133 (**A**), Nup98 (**B**) and TPR (**C-D**) were
876 quantified and box plots generated as described in Materials and Methods. The
877 mean value was set at 1 for *WT* mESCs. For each cell line, the number of cells
878 quantified (N), the number of distinct experiments [n], the mean value and standard
879 deviation are indicated. In (**D**), cells were treated with EtOH (control) or Auxin as
880 indicated.

881

882

883 **Figure 4: Quantification of nuclear sizes in *Seh1* mutant cell lines.**

884 Quantification of nuclear surface was performed as described in Materials and
885 Methods. The mean value was set at 1 for *WT* mESCs. Graphs show average and
886 standard deviation of nuclear surface values from [n] independent experiments
887 (displayed as dots). Unless specified by lines, samples were compared to *WT* for
888 statistical analyses (see Materials and Methods)

889

890 **Figure 5: *Mios*$^{-/-}$ mESCs do not mimic the growth and differentiation defects of**
891 ***Seh1*$^{-/-}$ mESCs, nor their decreased NPC density and nuclear size.**

892 **A.** Whole cell extracts of *WT*, *Seh1*$^{-/-}$ (#1 and #2) and *Mios*$^{-/-}$ mESCs (three
893 independent clones) were analyzed by western-blot using the indicated antibodies.
894 Molecular masses are indicated on the right (kDa). **B**. Immunoprecipitation
895 experiment using anti-Seh1 antibodies and *WT*, *Mios*$^{-/-}$ (#1 and #2), or *Seh1*$^{-/-}$ (#1)
896 mESC protein extracts. Inputs and eluates (20x equivalent) were analyzed by western
897 blot using the indicated antibodies. Molecular markers are indicated on the right
898 (kDa). **C-D.** Cell growth analyses (using percentage of confluence as proxy) were
899 performed with the IncuCyte® system for *WT*, *Seh1*$^{-/-}$ and three distinct *Mios*$^{-/-}$
900 clones at pluripotent state (**C**), and upon neuroectodermal differentiation (**D**). Error
901 bars correspond to the standard deviation arising from the indicated number of

902 independent experiments [n]. Statistical analyses were performed at the last time-
903 points. Brackets indicate statistics performed using all values from cell lines bearing a
904 given mutation, compared to *WT* (see Materials and Methods). **E-F.** Quantifications
905 of TPR signal intensity at the NE (**E**, presented as box plots) and of the nuclear
906 surface (**F**, graphs presenting the mean values and standard deviations from [n]
907 distinct experiments, each displayed as a dot) were performed for *WT*, *Seh1*$^{-/-}$ and
908 two *Mios*$^{-/-}$ clones as described in Materials and Methods. For each cell line, the total
909 number of cells (N) acquired in [n] distinct experiments, and the mean and standard
910 deviation values are indicated. For statistical analyses (see Materials and Methods)
911 samples were compared to *WT.* Note that the mild (9%) increase in TPR density in
912 *Mios*$^{-/-}$ # 1 mESCs was not observed for *Mios*$^{-/-}$ #2 cells and likely reflects a clonal-
913 related variation not linked to the lack of Mios. Note that data for *WT* and *Seh1*$^{-/-}$
914 mESCs (used as reference strains) shown in panels C, D and F, include some data
915 from experiments already presented in Figs. 1D-E and 4A.

916

917 **Figure 6: Impact of Y-complex short arm mutations on mESC proliferation and**
918 **differentiation.**
919 **A.** Predicted model of human Nup43 (shown in purple), Nup85 (blue and yellow) and
920 Seh1 (red) interactions (von Appen et al., 2015; PDB code: 5A9Q) visualized using
921 Pymol. The β-sheets within the N-terminal domain of Nup85 that are deleted in the
922 ΔE2-GFP/mCherry-Nup85 fusions are shown in yellow. **B.** Whole cell extracts of the
923 indicated cell lines were analyzed by western-blot using anti-Seh1, -Nup43, -Nup85,
924 and γ-tubulin antibodies. Two-and four fold dilution (1/2, 1/4) of the *WT* mESC
925 extract were also loaded. Molecular markers are indicated on the right (kDa). **C-D.**
926 Cell growth analyses were performed with the IncuCyte® system for *WT*, *Seh1*$^{-/-}$,
927 *ΔE2-GFP-Nup85* and *Nup43*$^{-/-}$ mESCs at pluripotent state (**C**), and upon
928 neuroectodermal differentiation (**D**). Error bars correspond to the standard deviation
929 arising from [n] independent experiments. Statistical analyses were performed at the
930 last time-points. Brackets indicate statistics performed using all values from cell lines
931 bearing a given mutation, compared to *WT* (see Materials and Methods). Note that

932 data for *WT* and *Seh1*$^{-/-}$ (used as reference strains) shown in panels **C-D** include
933 experiments already presented in Fig. 1 D-E.
934
935 **Figure 7: Quantification of NPC density and nuclear size in *ΔE2-GFP-Nup85* and**
936 ***Nup43*$^{-/-}$ mESC lines.**
937 **A-C.** Normalized signals intensities at the NE of Nup133 (**A**), Nup98 (**B**) and TPR (**C),**
938 (presented as box plots) and nuclear surfaces (**D;** graphs presenting the mean values
939 and standard deviations from [n] distinct experiments, each displayed as a dot) were
940 quantified as described in Materials and Methods. The number of cells (N), and of
941 distinct experiments [n], the mean value and standard deviation are indicated. For
942 statistical analyses (see Materials and Methods) samples were compared to *WT.*
943 Note that data for *WT* and *Seh1*$^{-/-}$ (used as reference strains) include experiments
944 already presented in Fig. 3.
945
946 **Figure 8. Impaired GFP-Seh1 localization at NPCs and Kinetochores in *ΔE2-mCherry-***
947 ***Nup85* mESCs.**
948 **A-B.** Representative spinning disk images (single z-section) of interphase (**A**) and
949 mitotic (**B**) *GFP-Seh1* cells (left) mixed with *ΔE2-mCherry-Nup85/GFP-Seh1* cells
950 (right). Scale bars, 10 µm. **C-D.** GFP-Seh1 intensity at NE (**C**) and at kinetochores (**D**)
951 was quantified in *GFP-Seh1* and *ΔE2-mCherry-Nup85/GFP-Seh1* for the indicated
952 number of cells (N) acquired in [n] independent experiments as described in
953 Materials and Methods. Values were normalized for each field (**C**) or for each
954 experiment (**D**) to the average intensity of the signal acquired for *GFP-Seh1* cells at
955 the NE and kinetochores, respectively.



Gonzalez-Estevez, Verrico, *et al.*, Figure 1



Gonzalez-Estevez, Verrico, *et al.*, Figure 2



	WT	Seh1-/- #1	Seh1-/- #2	Seh1-/- #3	Rescue #1	Rescue #2
mean ± SD	1.00 ± 0.26	0.64 ± 0.18	0.63 ± 0.30	0.62 ± 0.20	0.96 ± 0.21	0.88 ± 0.19
N [n]	472[9]	322[7]	112[3]	280[6]	89[3]	103[3]



	WT	Seh1-/- #1	Seh1-/- #2	Seh1-/- #3	Rescue #1	Rescue #2
mean ± SD	1.00 ± 0.23	0.71 ± 0.18	0.77 ± 0.20	0.66 ± 0.18	0.92 ± 0.20	0.95 ± 0.20
N [n]	562[5]	119[3]	133[3]	93[3]	186[4]	152[3]



	WT	Seh1-/- #1	Seh1-/- #2	Seh1-/- #3	Rescue #1	Rescue #2
mean ± SD	1.00 ± 0.25	0.72 ± 0.17	0.83 ± 0.21	0.77 ± 0.2	0.98 ± 0.17	0.89 ± 0.17
N [n]	345 [5]	223 [4]	124 [2]	245 [3]	108 [3]	135 [2]



	WT	GFP-mAID-Seh1#1	WT	GFP-mAID-Seh1#1	WT	GFP-mAID-Seh1#1
	control		Auxin 48h		Auxin 7-11 days	
mean ± SD	1.00 ± 0.25	0.98 ± 0.21	1.00 ± 0.25	0.66 ± 0.16	1.00 ± 0.23	0.66 ± 0.15
N [n]	258 [6]	350 [6]	233[6]	345[6]	141[3]	166[3]

Gonzalez-Estevez, Verrico, *et al.*, Figure 3



	WT	Seh1-/- #1	Seh1-/- #2	Seh1-/- #3	Rescue #1	Rescue #2
mean ± SD	1.00	0.91 ± 0.03	0.88 ± 0.01	0.88 ± 0.02	1.02 ± 0.03	0.99 ± 0.06
N [n]	1872[9]	1067[6]	252[3]	281[3]	411[4]	375[4]

	WT control	GFP-mAID-Seh1#1 control	WT Auxin 48h	GFP-mAID-Seh1#1 Auxin 48h
mean ± SD	1.00	0.97 ± 0.26	1.00	0.91 ± 0.02
N [n]	224 [3]	380 [3]	459 [4]	494 [4]

Gonzalez-Estevez, Verrico, *et al.*, Figure 4



Gonzalez-Estevez, Verrico, *et al.*, Figure 5



Gonzalez-Estevez, Verrico, *et al.*, Figure 6



	WT	Seh1 #1	Nup43 #1	Nup43 #2	ΔE2-GFP-Nup85 #1	ΔE2-GFP-Nup85 #2
mean± SD	1.00 ± 0.25	0.66 ± 0.18	0.68 ± 0.18	0.67 ± 0.20	0.74 ± 0.17	0.74 ± 0.17
N [n]	331[7]	199[6]	87[3]	101[3]	173[6]	91[3]



	WT	Seh1 #1	Nup43 #1	Nup43 #2	ΔE2-GFP-Nup85 #1	ΔE2-GFP-Nup85 #2
mean± SD	1.00 ± 0.23	0.71 ± 0.18	0.75 ± 0.19	0.78 ± 0.21	0.78 ± 0.16	0.81 ± 0.17
N [n]	562[5]	119[3]	150[3]	123[3]	141[3]	110[3]



	WT	Seh1 #1	Nup43 #1	Nup43 #2	ΔE2-GFP-Nup85 #1	ΔE2-GFP-Nup85 #2
mean± SD	1.00 ± 0.22	0.71 ± 0.16	0.82 ± 0.2	0.81± 0.22	0.76 ± 0.17	0.83 ± 0.23
N [n]	373 [8]	257 [6]	134 [3]	135 [3]	236 [5]	168 [3]



	WT	Seh1 #1	Nup43 #1	Nup43 #2	ΔE2-GFP-Nup85 #1	ΔE2-GFP-Nup85 #2
mean ± SD	1.00	0.91 ± 0.01	0.96 ± 0.03	0.94 ± 0.06	1.0 ± 0.02	0.96 ± 0.03
N [n]	1888[14]	1067[6]	445[4]	404[3]	1706[10]	546[4]

Gonzalez-Estevez, Verrico, *et al.*, Figure 7





mean± SD	1.00 ± 0.22	0.27 ± 0.07	0.26 ± 0.07
N [n]	352 [3]	275 [3]	132 [1]



mean± SD	1.00 ± 0.21	0.07 ± 0.07	0.08 ± 0.05
N [n]	44 [5]	25 [4]	30 [3]

Gonzalez-Estevez, Verrico, *et al.*, Figure 8

Inventory of Supplementary Material

Supplemental Figures and Figure legend:

Figure S1, related to Fig. 1: Auxin-induced GFP-mAID-Seh1 degradation in mESCs recapitulates *Seh1*$^{-/-}$ phenotypes

Figure S2, related to Fig. 2: *Seh1*$^{-/-}$ mESCs have prolonged mitosis despite proper localization of the Y-complex at kinetochores

Figure S3, related to Figs. 6-8: Characterization of the *ΔE2-GFP-Nup85* and *ΔE2-mCherry-Nup85* cell lines

Figure S4, related to Materials and Methods and Tables S2 and S3: Strategies for CRISPR-Cas9-mediated cell line establishment via homologous recombination**.**

Supplemental Tables:

Table S1: Plasmids used in this study

Table S2: Cell lines used in this study

Table S3: Sequences of gRNAs and Primers used in this study

Table S4: Antibodies used in this study

References cited in Supplemental Figures and Tables

Supplemental Movies, related to Figure 1:

Examples of neuroectodermal differentiation experiments as exported from IncuCyte® device. Time and scale bars are indicated

- Movie S1: *WT*
- Movie S2: *Seh1* $^{-/-}$ *#1*
- Movie S3: *Rescue #2*



Figure S1, related to Fig. 1. Auxin-induced GFP-mAID-Seh1 degradation in mESCs recapitulates *Seh1*$^{-/-}$ phenotypes. A-B. GFP-mAID-Seh1 localizes at NE in interphase cells (**A**; a single confocal plane is presented) and is enriched at kinetochores in mitotic cells (**B**; a projection of 9 optical sections is presented). After 30 minutes of auxin treatment, the GFP signal is only slightly decreased at the NE in interphase cells but no longer detectable in mitotic cells (arrowhead). Longer treatments (4 to 6 hours) with auxin lead to a progressive decrease of the NE signal, and to the appearance of GFP negative cells (*, likely corresponding to cells that went through mitosis). Scale bars, 10 µm. **C.** Localization of Nup133 in interphase (upper panels) and mitotic (lower panels) *GFP-mAID-Seh1* #1 mESCs after 24h of auxin treatment. The arrowheads point to the kinetochores that are labelled by Nup133 despite the lack of GFP-mAID-Seh1. Scale bar, 10 µm. **D.** Whole cell extracts from *WT-OsTIR* and *GFP-mAID-Seh1 #1* mESCs, treated or not with auxin for the indicated time, were analyzed by western blot using anti-Seh1 (top) and an anti-gamma-tubulin antibodies (bottom, used as loading control). 1/2 and 1/4 dilutions of *WT (OsTIR)* and non-treated *GFP-mAID-Seh1* #1 cell extracts were also loaded. Molecular weights are indicated (kilodaltons). **E.** Cell growth at pluripotent stage of the indicated cell lines was analyzed using cell confluence measurements with the IncuCyte® system. Cells were treated with Auxin for 18 to 26 h prior to time 0. Error bars correspond to standard deviations from 3 independent experiments. **F.** The % of cell confluence upon neuroectodermal differentiation was quantified with the IncuCyte® system. Cells were exposed to Auxin at the beginning of differentiation (day 0). Error bars correspond to standard deviations of 4 (*GFP-mAID-Seh1* #1 ad *OsTIR* WT) or 3 (*GFP-mAID-Seh1* #2 and *Seh1*$^{-/-}$ #1) distinct wells acquired in 3 and 2 independent experiments, respectively. Statistical analyses were performed using the two-tailed Paired Student's t-test (See Materials and Methods), by comparing all control (-Auxin) or treated (+Auxin) mutant cell lines to *Wt (OsTIR)* -Auxin or +Auxin, respectively.



Figure S2, related to Fig. 2: *Seh1*$^{-/-}$ mESCs have prolonged mitosis despite proper localization of the Y-complex at kinetochores

A. Quantification of the time spent from prometaphase to anaphase in *WT* and *Seh1*$^{-/-}$ mESCs. Each dot represents one cell and the median time is represented with a black bar. The number (N) of cells, quantified in 3 independent experiments is indicated**. B, C.** Representative spinning-disk images of mitotic *WT* and *Seh1*$^{-/-}$ mESCs, immunolabeled with (**C**) anti-Nup85 or (**D**) anti-Nup133, along with CREST serum (centromere marker) and stained with DAPI. A projection of three Z sections is presented. 3-fold enlargements of the boxed areas are also presented. Scale bars, 10 µm. **D.** Representative plots of the last steps of our ImageStream® cell cycle analyses (*WT* mESCs). Top: the G1, S and G2/M phases of the cell cycle were defined based on DNA content (DAPI intensity) and EdU incorporation (AF647 channel). Middle: the G2 and M (Mitotic) population were then discriminated based on DAPI intensity and area. Bottom: bright Field (BF) and corresponding DAPI images of representative cells defined by these gating as G2 (orange) or mitotic (blue) are presented.

A



B

	Antibody :	control	anti-Nup107		anti-Nup85	
	Cells :	*WT*	*WT*	*ΔE2- GFP-Nup85*	*WT*	*ΔE2- GFP-Nup85*
Y-complex Nups [a]	Seh1l		106		34	
	Nup85		185	37	215	431
	Nup43		55	19	47	56
	Nup160		340	125	255	657
	Nup37		61	34	25	116
	Nup133		536	349	345	676
	Nup107		192	99	95	453
	Nup98-96 [b]	16 [c]	139	200	204	385 [c]
	Sec13		27	15	24	60

C



Figure S3, related to Figs 6-8. Characterization of the *ΔE2-GFP-Nup85* and *ΔE2-mCherry-Nup85* cell lines. (**A**) Representative spinning disk images (single plane) of interphase (left) and mitotic (right) *ΔE2-GFP-Nup85* mESCs fixed and stained with DAPI. Scale bar, 10 µm. **B**. The table provides the Mascot score for an immunoprecipitation experiment (see Materials and Methods) using either a pre-immune serum (control) or anti-Nup107 or -Nup85 antibodies, to pull down the Y-complex from *WT* or *ΔE2-GFP-Nup85* mESC protein extracts. [a]Elys/AHCTF1 was not identified in this immunoprecipitation experiment. [b]The autoproteolytic clivage of the Nup98-Nup96 precursor generates Nup98 and Nup96 (Fontoura et al., 1999); only the latter is a stable component of the Y-complex. Nearly all (35 out of 36) peptides identified in these immune pellets originates from Nup96. [C] Samples in which the Nup98 peptide was identified. **C.** Whole cell extracts of the indicated cell lines were analyzed by western-blot using anti-Nup85, -Seh1, -Nup43, and -GAPDH antibodies. Two-and four fold dilution (1/2, 1/4) of the *WT* and *GFP-Seh1* mESC extracts were also loaded. Molecular markers are indicated on the right (kDa).



Figure S4, related to Materials and Methods and Tables S2 and S3: Strategies for CRISPR-Cas9-mediated cell line establishment via homologous recombination.

The constructs used for homologous recombination (**A**, plasmid digested with the indicated restriction enzyme, and **B-C**, PCR products: the sequences of the oligonucleotides (arrows) used to amplify the template are listed in **Table S3**) leading to the indicated cell lines are represented above each targeted genomic locus (**A**: *Tigre*, **B:** *Seh1*, and **C**: *Nup85*). The sequences targeted by the gRNAs (red boxes), the sequences used for homology-directed repair (light grey boxes), and when relevant, the position of the exons and the first ATG are displayed. The size of the various segments is indicated in bp. Note that the construct used for GFP-Seh1 expression (**A.** *Seh1 rescue* and **B.** *GFP-Seh1* lines) further contains a non-functional 38 amino-acid long fragment of mAID. In **B.**, the red star indicates the position of silent CRISPR/Cas9 blocking mutations introduced in one Seh1 HR-arm.

Table S1: Plasmids.

Plasmids used (sequence upon request)	Source	Identifier
pX-280_Cas9WT-EGFP-Seh1gRNA1 - Seh1gRNA 2	This paper	#1808
pU6-sgTigre_CBh-Cas9-T2A-mCherry-3UTR	From P. Navarro Gil and N. Festuccia. (Festuccia et al., 2019)	#2061
Tigre HR-pCAG-EGFP-mSeh1-*Tigre* HR	This paper	#2077
Tigre HR-pCAG-OsTir-T2A-NeoR-*Tigre* HR	From P. Navarro Gil and N. Festuccia. (Festuccia et al., 2019)	#2064
pX-853_Cas9WTmCherry Seh1-gRNA1	This paper	#2098
pCMV-EGFP-mAID-hSeh1	This paper	#2100
GeneArt CRISPR Nuclease Vector (OFP_Cas9)	Invitrogen, Carlsbad, CA	A21174
GeneArt CRISPR pOFP-Cas9-Mios gRNA2	This paper	#2110
GeneArt CRISPR pOFP-Cas9-Mios gRNA4	This paper	#2111
GeneArt CRISPR pOFP-Cas9-Nup43 gRNA1	This paper	#2104
pX-672-Cas9HF-mCherry-gRNANup85-1_ gRNANup85-2	This paper	#2005
pX-864-Cas9HF-GFP-gRNANup85-1_ gRNANup85-2	This paper	#2101
pBOS-H2B-Cherry-IRES-Neo	From Doye lab (Bolhy et al., 2011)	#824
pBOS-H2B-GFP-IRES-Neo	From Doye lab (Bolhy et al., 2011)	#805

Table S2, related to Experimental Procedures. Cell lines used in this study

NAME	SOURCE (IF COMMERCIAL) OR DESIGN FOR CELL LINES GENERATED IN THIS STUDY	IDENTIFIER	Plate ref.	MUTATIONS (genomic sequences set at 1 for the first ATG)	Chromosome count
MEF (DR4)	Applied StemCell	ASF-1001	-	-	-
WT mESCs (HM1)	ThermoFisher Scientific (Selfridge et al., 1992)	MES4303	-	-	40
***Seh1*$^{-/-}$**	Parental cell line: HM1 Cas9 & gRNA plasmid: pX-280_Cas9WT-EGFP-Seh1gRNA1 - Seh1gRNA 2 HR template: (200 bp synthetic oligonucleotide initially designed to facilitate screening)	*Seh1*$^{-/-}$ #1	A18	Only one PCR band observed suggesting that both alleles bear the same mutation. Allele 1 (and 2): Deletion of 351bp from -317 to +33. Insertion of 32bp (from HR template) at +71.	40 Chr (>60%)
		Seh1$^{-/-}$ #2	B42	Allele 1: 1bp indel (c>a) at -2 plus Deletion of 77bp from +4 to +77. Insertion of 31 bp (from HR template) at +4. Allele 2: Deletion of 30bp from -2 to +27; one bp deletion at +70.	40 Chr (>60%)
		Seh1$^{-/-}$ #3	B37	Allele 1: Deletion of 52 bp from +19 to +71 Allele 2: Deletion of 15bp from +13 to +27; one bp deletion at +70.	40 Chr (>60%)
Seh1-Rescue	Parental cell line: Seh1$^{-/-}$ *#1* mESCs Cas9 & gRNA plasmid: pU6-sgTIGRE_CBh-Cas9-T2A-mCherry-3UTR HR template: linearized (with DrdI) TIGRE HR-pCAG-EGFP-mSeh1-TIGRE HR (#2077)(**Figure S4**)	*Seh1-Rescue* #1	R11G	Rescue of Seh1$^{-/-}$ #1 (A18). Insertion of pCAG-GFP-Seh1 in only one of the *TIGRE* alleles	40 Chr (55%) 39 Chr (45%)
		Seh1-Rescue #2	R11F	Rescue of Seh1 KO A18 (#1). Insertion of pCAG-GFP-Seh1 in only one of the *TIGRE* alleles	40 Chr (>60%)
OsTIR	Parental cell line: HM1 Cas9 & gRNA plasmid (s): pU6-sgTIGRE_CBh-Cas9-T2A-mCherry-3UTR HR template: linearized (with EcoRV) TIGRE HR-pCAG-OsTir-T2A-NeoR-TIGRE HR (#2064) (**Figure S4**)	*OsTIR*	11B	Insertion of pCAG-OsTir-T2A-NeoR in only one of the *TIGRE* alleles.	42Chr (>60%)

Table S2- continued

NAME	DESIGN OF THE CELL LINES	IDENTIFIER	Plate ref.	**MUTATIONS** (genomic sequences set at 1 for the first ATG)	Chromosome count
GFP-mAID-Seh1	Parental cell line: *OsTIR* Cas9 & gRNA plasmid (s): **pX-853** _Cas9WTmCherry Seh1-gRNA1 HR template: PCR product: HR-EGFP-mAID-mSeh1 (gRNA resistant)-HR; amplification of plasmid #2100 with primers indicated in **Figure S4** and **Table S3**	*GFP-mAID-Seh1* #1	F9	Alleles 1 and 2: GFP-mAID-Seh1	42Chr (>60%)
		GFP-mAID-Seh1 #2	E6	Allele 1: GFP-mAID Seh1 Allele 2: *Seh1* KO; 1 bp insertion at + 18	42Chr (>60%)
***Mios*$^{-/-}$**	Parental cell line: HM1/ Cas9 & gRNA plasmid (s): GeneArt CRISPR pOFP-Cas9-Mios gRNA2 GeneArt CRISPR pOFP-Cas9-Mios gRNA4 HR template: none	*Mios*$^{-/-}$ #1	5C	Only one PCR band observed suggesting that both alleles bear the same mutation. Allele 1 (and 2): Deletion of 593 bp from -310 to 282.	40 Chr (>60%)
		Mios$^{-/-}$ #2	7C	Allele 1: Deletion of 33bp from +74 to 106. Allele 2: Deletion of 3 bp from +84 to +86	40 Chr (>60%)
		Mios$^{-/-}$ #3	7D	Allele 1: Deletion of 3bp from +83 to 85 and of 7 bp from 195 to 201. Allele 2: Replacement from bp 85 C by GT (=1bp) and insertion of a T after bp 196.	40 Chr (>60%)
ΔE2-GFP-Nup85	Parental cell line: HM1 Cas9 & gRNA plasmid (s): **pX-672-**Cas9HF-mCherry-gRNANup85-1_ gRNANup85-2 HR template: PCR product: HR-EGFP-HR (**Figure S4**); amplification of EGFP with primers indicated in Figure S4 and Table S3	*ΔE2-GFP-Nup85* #1	B2	Allele 1: In frame integration of GFP in exon 2 and deletion from bp 639 to 716. Allele 2: *Nup85* KO; deletion of 2bp at +633-634 leading to premature stop codon.	41 Chr (56%) 40 Chr (25%)
		ΔE2-GFP-Nup85 #2	B10	Allele 1: In frame integration of GFP in exon 2 and deletion from bp 639 to 716. Allele 2: *Nup85* KO; Deletion of 20 bp from 622 to 641.	42 Chr (57%) 41 Chr (29%) 40 Chr (14%)
		ΔE2-GFP-Nup85 #3	B3	Allele 1: In frame integration of GFP in exon 2 and deletion from bp 639 to 716. Allele 2: *Nup85* KO; deletion of 13 bp from 627 to 647	42 Chr (>60%)

Table S2- continued

NAME	DESIGN OF THE CELL LINES	IDENTIFIER	Plate ref.	**MUTATIONS** (genomic sequences set at 1 for the first ATG)	Chromosome count
GFP-Seh1	Parental cell line: HM1 Cas9 & gRNA plasmid (s): **pX-853** _Cas9WTmCherry Seh1-gRNA1 HR template: PCR product HR_EGFP-mSeh1 (gRNA resistant)-HR. Amplification of plasmid #2077 with primers indicated in **Figure S4** and **Table S3**	*GFP-Seh1*	B10	Allele 1: *GFP-Seh1*. In frame N-term integration of GFP at +4 in *Seh1* sequence. Allele 2: *Seh1* KO. Deletion from -2 to +27.	40 Chr (>60%)
ΔE2-mCherry-Nup85	Parental cell line: *GFP-Seh1* Cas9 & gRNA plasmid (s): pX-864-Cas9HF-GFP-gRNANup85-1_ gRNANup85-2 HR template: PCR product HR-mCherry-HR (**Figure S4**); amplification of mCherry with primers indicated in Figure S4 and Table S3	*ΔE2-mCherry-Nup85* #1	B6	Allele 1: in frame mCherry integration in exon2 and deletion from bp 639 to 716. Allele 2: *Nup85 KO*. Deletion of 8bp (+630 -- +638) and of 10 bp (+706 to +716) in exon 2.	41 Chr (>60%)
		ΔE2-mCherry-Nup85 #3	C5	Same genotype as above (#1 =B6)	41 Chr (>60%)
		ΔE2-mCherry-Nup85 #2	G4	Allele 1: in frame mCherry integration in exon2 and deletion from bp +639 to +716. Allele 2: *Nup85 KO*. Deletions of 42 (+635 -- + 677; 12 bp also inserted) and 33 bp (+683 -- +716; 9 bp also inserted) in exon 2.	41 Chr (>60%)
Nup43$^{-/-}$	Parental cell line: HM1 Cas9 & gRNA plasmid (s): GeneArt CRISPR pOFP-Cas9-Nup43 gRNA1 HR template: none	*Nup43$^{-/-}$* #1	E4	Allele 1: *Nup43 KO*. Deletion of 40 bp from +22 to +62. Allele 2: *Nup43 KO*. Deletion of 32 bp from +38 to +70.	40 Chr (>60%)
		Nup43$^{-/-}$ #2	B5	Allele 1: *Nup43 KO*. Insertion of 1 bp at +52. Allele 2: *Nup43 KO*. Insertion of 2 bp at +52.	40 Chr (>60%)

Table S3: **Sequences of gRNAs and PCR primers used to generate the template for homology-directed repair (HDR)**

Sequences of gRNAs used in this study		
IDENTIFIER	**SEQUENCE**	**SOURCE**
Seh1-gRNA1 [Exon 1 Fw]	TTGTGGCGCGCAGCATCG	This paper
Seh1-gRNA2 [Exon 1 Rv]	TGGCCATCCGGCGCCCG	This paper
sgTigre	ACTGCCATAACACCTAACTT	This paper
Mios-gRNA2 [Exon 3 Fw]	CCTATATGAAATGTGTTGCG	This paper
Mios-gRNA4 [Exon 3 Fw]	AGAATTGAGCCTTTATCATG	This paper
ΔE2-GFP-Nup85-gRNA1 [Exon 2 Rv]	TTCTTCTTGGAATTCACACC	This paper
ΔE2-GFP-Nup85-gRNA2 [Exon 2 Fw]	CTTCCTTCAACCAAACAGGT	This paper
Nup43-gRNA1 [Exon 1 Fw]	AAATTAGCAAAACCCGCTGG	This paper

PCR primers used to generate the template for homology-directed repair (HDR)		
IDENTIFIER	**SEQUENCE**	**SOURCE**
AG100 [Fw, HDR left arm] *GFP-Seh1, GFP-mAID-Seh1*	CCCGCGCAGGGCGTGTCCCTCGGGGCGTGGCGCGCCGGGGCC GACGCGGGCGGGCAGGCGAGGGCCGACGTGCCGTACGTGCCT CCGCGGTGG	This paper
AG101 [Fw, HDR left arm] *GFP-Seh1*	TACGTGCCTCCGCGGTGGTCCGGGGGCTGCGGGCCGCACCGC CGCCCTCTCGGAGGCGGGCCCGGCAGACGGCGGCGGCCATGG TTTCCTGCCAAAAATCAAGC	This paper
AG103 [Rv, HDR right arm] *GFP-Seh1, GFP-mAID-Seh1*	GCGCCGCCTCCCTCCCCTCCCGGCCGGGCAGCGGCGAGTGCCG CGCGCACCTTGACGCTCTGATCGCTGGAGCAGGTGGCCATCCG GCGCCCGTGGAAGTCG	This paper
AV01 [Rv, HDR right arm] *GFP-Seh1*	CGGCGCCCGTGGAAGTCGAAAGACACATCGTGGATGAGGTCC TTGTGGTCCGCCGCGATAGACCGGGCGACGAAGGATCTGAGT CCGGACTTGTACAGC	This paper
AV04 [Fw, HDR left arm] *GFP-mAID-Seh1*	CGGCGCCCGTGGAAGTCGAAAGACACATCGTGGATGAGGTCC TTGTGGTCCGCCGCGATAGACCGGGCGACGAAGGATCTGAGT CCGGATTTATA	This paper
AV05 [Rv, HDR right arm] *GFP-mAID-Seh1*	TACGTGCCTCCGCGGTGGTCCGGGGGCTGCGGGCCGCACCGC CGCCCTCTCGGAGGCGGGCCCGGCAGACGGCGGCGGCCATGG TGAGCAAGGGCGAGGAG	This paper
BR3466 [Fw2, HDR left arm] *ΔE2-GFP[mCherry]-Nup85*	TCATTGGATACGACCTAGGCTGTTCGCCTGGTGTATGGTGTTCG CAGTTACACTTGGAAGTTGAATGGACAGTTGTAGGGCTAAC	This paper
BR3467 [Fw1, HDR left arm] *ΔE2-GFP[mCherry]-Nup85*	GAATGGACAGTTGTAGGGCTAACAGCTCCTGTGCCTCCTTATG TCTTACTAGTGGATTCCAGGTATGGTGAGCAAGGGCGAGGAG	This paper
BR3468 [Rv1, HDR right arm] *ΔE2-GFP[mCherry]-Nup85*	CAGTTTCCTGCCTCAGAGAGTCAACCAATGTGCCAAGACAGAT GTGAAAAAGAACTGCCTACCCTTGTACAGCTCGTCCATGCCG	This paper
BR3469 [Rv, HDR right arm] *ΔE2-GFP[mCherry]-Nup85*	GCAACTTGTCTCAAAATAGCAAAAAAACAAAGTTTCAAAAATA AAAATATTGCCAAATAACTCCAGTTTCCTGCCTCAGAGAGTC	This paper

Table S4: **Antibodies**

Primary antibodies	Dilution	Source	Identifier
Human autoantibody against-centromeres (CREST serum)	IF: 1/500	ImmunoVision, Springdale, AR	HCT-0100
Rabbit polyclonal anti-GAPDH	WB: 1/2000	Trevigen,Minneapolis, MN	2275-PC100
Mouse anti-gamma-tubulin	WB: 1/50000	Abcam, San Francisco, CA	Ab11316
Rabbit polyclonal antibody anti-Mios	WB: 1/1000	Cell signalling, Danvers, MA	#13557
Affinity-purified rabbit polyclonal anti-Nup43 antibody	WB: 1/1000	From Doye lab (Zuccolo et al., 2007)	# 571/08-111-C1
Rabbit polyclonal anti-mNup85 serum	WB: 1/2000 IF: 1:1000 IP: 1/10	From D. Forbes (Harel et al., 2003)	N/A
Rabbit monoclonal antibody anti-Nup98 C39A3	IF: 1/20	Cell signalling	#2598
Rabbit polyclonal anti-Nup107	WB: 1/1000 IP: 1/10	From Doye lab (Belgareh et al., 2001)	#520-82
Rat monoclonal anti-mouse Nup133 antibody #74; clone 9C2H8)	IF: 1/100	From Doye lab (Berto et al., 2018)	N/A
Rabbit polyclonal antibody anti-Seh1	WB: 1/1000 IP: 1/500	Abcam, San Francisco, CA	ab218531
Rabbit polyclonal antibody anti-Tpr	IF: 1/200	Abcam, San Francisco, CA	ab84516
Rabbit polyclonal antibody anti Ostir	WB: 1/1000	From M.T. Kanemaki (Natsume et al., 2016)	N/A
Rabbit polyclonal antibody anti- Wdr24	WB: 1/1000	Proteintech, Manchester, UK	20778-1-AP

Secondary antibodies	Dilution	Source	Identifier
Cy™3 AffiniPure Donkey anti-rabbit	IF: 1/1000	Jackson ImmunoRes, West Grove, PA	711-165-152
Cy™3 AffiniPure Donkey anti-rat	IF: 1/1000	Jackson ImmunoRes	712-165-153
Cy™3 AffiniPure Goat anti-rabbit	IF: 1/1000	Jackson ImmunoRes	111-165-144
AlexaFluor 568 Donkey anti-rabbit	IF: 1/1000	ThermoFisher Scientific	A10042
Alexa 647 Donkey anti-human	IF: 1/500	Jackson ImmunoRes	709-605-149
Cy™5 AffiniPure Donkey anti-rat	IF: 1/1000	Jackson ImmunoRes	712-175-153
Peroxidase AffiniPure Donkey anti-rabbit	WB: 1/5000	Jackson ImmunoRes.	711-035-152
Peroxidase AffiniPure Goat anti-mouse	WB: 1/5000	Jackson ImmunoRes.	115-035-068
Peroxidase AffiniPure Goat anti-ratCy™5 AffiniPure Donkey Anti-Rat	WB: 1/5000	Jackson ImmunoRes.	112-035-167
Rabbit TrueBlot ®: Anti-Rabbit IgG HRP	WB: 1/1000	Rockland, Limerick, PA	18-8816-33

References cited in Supplemental Figures and Tables

Belgareh, N., Rabut, G., Bai, S.W., van Overbeek, M., Beaudouin, J., Daigle, N., Zatsepina, O.V., Pasteau, F., Labas, V., Fromont-Racine, M.*, et al.* (2001). An evolutionarily conserved NPC subcomplex, which redistributes in part to kinetochores in mammalian cells. *J Cell Biol* **154**, 1147-1160.

Berto, A., Yu, J., Morchoisne-Bolhy, S., Bertipaglia, C., Vallee, R., Dumont, J., Ochsenbein, F., Guerois, R., and Doye, V. (2018). Disentangling the molecular determinants for Cenp-F localization to nuclear pores and kinetochores. *EMBO Rep* **19***,* e44742.

Bolhy, S., Bouhlel, I., Dultz, E., Nayak, T., Zuccolo, M., Gatti, X., Vallee, R., Ellenberg, J., and Doye, V. (2011). A Nup133-dependent NPC-anchored network tethers centrosomes to the nuclear envelope in prophase. *J Cell Biol* **192**, 855-871.

Festuccia, N., Owens, N., Papadopoulou, T., Gonzalez, I., Tachtsidi, A., Vandoermel-Pournin, S., Gallego, E., Gutierrez, N., Dubois, A., Cohen-Tannoudji, M.*, et al.* (2019). Transcription factor activity and nucleosome organization in mitosis. *Genome Res* **29**, 250-260.

Fontoura, B.M.A., Blobel, G., and Matunis, M.J. (1999). A conserved biogenesis pathway for nucleoporins: Proteolytic processing of a 186-kilodalton precursor generates Nup98 and the novel nucleoporin, Nup96. *J Cell Biol* **144**, 1097-1112.

Harel, A., Orjalo, A.V., Vincent, T., Lachish-Zalait, A., Vasu, S., Shah, S., Zimmerman, E., Elbaum, M., and Forbes, D.J. (2003). Removal of a single pore subcomplex results in vertebrate nuclei devoid of nuclear pores. *Mol Cell* **11**, 853-864.

Natsume, T., Kiyomitsu, T., Saga, Y., and Kanemaki, M.T. (2016). Rapid Protein Depletion in Human Cells by Auxin-Inducible Degron Tagging with Short Homology Donors. *Cell Rep* **15**, 210-218.

Zuccolo, M., Alves, A., Galy, V., Bolhy, S., Formstecher, E., Racine, V., Sibarita, J.B., Fukagawa, T., Shiekhattar, R., Yen, T.*, et al.* (2007). The human Nup107-160 nuclear pore subcomplex contributes to proper kinetochore functions. *EMBO J* **26**, 1853-1864.